dabigatran has been researched along with Bleeding in 1029 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (1.75) | 29.6817 |
| 2010's | 798 (77.55) | 24.3611 |
| 2020's | 213 (20.70) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Ma, L; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Chao, TF; Chen, MC; Chen, SW; Chu, PH; Chung, CM; Kuan, FC; Lin, YS; Lip, GYH; Wu, M; Wu, VC | 1 |
| Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H | 1 |
| Abuska, D; Afacan, G; Ersan, E; Hosseinzadeh, M; Karcioglu, O; Ozkaya, B; Yeniocak, S; Yilmaz, S; Zengin, S | 1 |
| Barnett-Griness, O; Gronich, N; Kotler, A; Saliba, W; Stein, N | 1 |
| Barnes, GD; DeCamillo, D; Haymart, B | 1 |
| Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Hernandez, I; Keshishian, A; Russ, C; Tsai, WL; Yuce, H | 1 |
| Hu, Z; Mao, J; Pan, J; Shen, Z; Shi, A; Su, C; Tao, H; Xu, F; Zhu, Z | 1 |
| Chu, H; Du, X; Feng, M; Fu, G; He, B; Liu, J; Wang, B; Wang, Z; Yu, Y; Zhuo, W | 1 |
| Li, J; Qian, Y; Weng, Z; Zhang, J | 1 |
| Chan, H; Hanna, M; Merriman, E; Royle, G; Stone, L | 1 |
| Luijkx, J; van 't Hof, A; Winkler, P | 1 |
| Abe, K; Amano, H; Asaoka, Y; Honda, T; Kodashima, S; Komatsuda, S; Kozuma, K; Manabe, D; Tanaka, A; Yamamoto, H; Yamamoto, T; Yanagisawa, D | 1 |
| Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C | 1 |
| Alioğlu, E; Altın, C; Bilgin, N; Çetin, N; Dalgıç, O; Ekmekçi, C; Kocabaş, U; Özpelit, ME; Pekel, N; Topaloğlu, C; Tülüce, K; Tunçer, E; Türk, UÖ; Türkoğlu, Eİ; Yavuz, V; Yüksel, K | 1 |
| Groll, A; Haefeli, WE; Meid, AD; Wirbka, L | 1 |
| de Vries, TI; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; Visseren, FLJ; Westerink, J | 1 |
| Camoin-Jau, L; Chevillard, L; Delrue, M; Deye, N; Dragoni, A; Gainnier, M; Malissin, I; Mégarbane, B; Siguret, V; Stépanian, A; Voicu, S | 1 |
| Davis, K; Khouli, C; Mihm, A; Nisly, SA; Sebaaly, J; Wooten, L | 1 |
| Nalezinski, S | 1 |
| Aslan, S | 1 |
| Cook, HE; Hewitt, JH; Patterson, EP; Randolph, AE | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
| Beretta, AE; Spigariolo, CB; Veraldi, S | 1 |
| Cui, YM; Hu, K; Liu, ZY; Ma, LY; Mu, GY; Wang, Z; Wang, ZN; Xiang, Q; Xie, QF; Zhang, HX; Zhou, S | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Lip, GYH; Lohmann, R; Lu, S; Ma, CS; Rothman, KJ; Teutsch, C | 1 |
| Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Kotalczyk, A; Lip, GYH; Ma, CS; Marler, S; Rothman, KJ; Teutsch, C | 1 |
| Murray, KT; Ray, WA | 1 |
| Gu, HQ | 1 |
| Hirohisa, I; Hiroshi, I; Hiroyuki, N; Masayori, S; Natsuko, SY; Yutaka, I | 1 |
| Chan, ECY; Soh, XQ; Tan, DS | 1 |
| Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y | 1 |
| Csajka, C; Daali, Y; Fontana, P; Gaspar, F; Guidi, M; Reny, JL; Terrier, J | 1 |
| Chung, MK; Dukes, J; Ezekowitz, MD; Gengler, BE; Gopinathannair, R; Lakkireddy, D; Lip, GYH; Mar, PL; Miletello, M; Noseworthy, PA; Olshansky, B; Perez, A; Reiffel, J; Tisdale, JE | 1 |
| Chandrasegaram, A; Peters, CD | 1 |
| Paik, J | 1 |
| Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Uchiyama, S; Wakayama, J; Yamashita, T; Yasaka, M | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, Q; Yu, M; Zong, L | 1 |
| Cao, S; He, T; Wu, X; Yu, B | 1 |
| Abbasi, G; Daei, M; Heidari, Z; Khalili, H | 1 |
| Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
| Chaudhury, P; Desai, MY; Harb, S; Johnston, D; Kapadia, S; Menon, V; Mentias, A; Michael, M; Nakhla, S; Saad, M; Saliba, W; Svensson, L; Wazni, O | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Guitard-Dehoux, D; Hanon, O; Jacoud, F; Mahé, I; Marant-Micallef, C; Née, M; Steg, PG; Van Ganse, E | 1 |
| Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P | 1 |
| Guo, R; Li, N; Sheng, R; Sun, X; Wang, J | 1 |
| Bi, G; Chen, J; Qin, X; Wu, F | 1 |
| Bessette, LG; Schneeweiss, S; Sreedhara, SK; Wang, SV | 1 |
| Bloch, J; Guillermin, A; Jenny, E; Volpe, M | 1 |
| Lameijer, H; Meijer, K; Mitrovic, D; Stapel, L; van Roon, E; Veeger, N | 1 |
| Amico, F; Colivicchi, F; Di Fusco, SA; Giubilato, S; Gulizia, MM; Lucà, F | 1 |
| Artang, R; Brod, C; Nielsen, JD | 1 |
| Beyene, K; Chan, AHY; Gong, J; Hayes, M; Munevar Aquite, O; Schauer, C; Wei, H | 1 |
| Bielecka, B; Gorczyca-Głowacka, I; Wożakowska-Kapłon, B | 1 |
| Ali, AK; Duffield, S; Gatto, N; Gibbs, L; Govil, P; Jaksa, A; Jonsson, P; Kent, S; Kincaid, L; Patrick, AR; Rowark, S; Sharma, M | 1 |
| Ricca Gonçalves, L; Robalo Nunes, A | 1 |
| Lameijer, H; Meijer, K; Mitrovic, D; van Elp, M; van Roon, E; Veeger, N | 1 |
| Chen, J; Chen, M; Fang, Z; Guan, C; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Gosselin, L; Lévy, C; Steichen, O; Vilcu, AM | 1 |
| Aronow, WS; Bahar, AR; Bahar, Y; Biswas, S; Gupta, R; Hajra, A; Mathai, SV; Safiriyu, I | 1 |
| Badve, SV; Deague, J; Dundon, BK; Hammett, C; Joseph, JE; Kerr, PG; Lo, S; Perkovic, V; Tran, HA; Wong, A | 1 |
| Guo, Z; Mao, J; Pan, J; Qian, C; Su, C; Tao, H; Zhu, X; Zhu, Z | 1 |
| Boivin Proulx, LA; Dorais, M; Legault, C; Lenglet, A; Perreault, S; Qazi, JZ | 1 |
| Antoniolli, M; Barrionuevo, B; Bernal, MI; Cigalini, IM; Lerech, E; Morcos, L; Scatularo, CE; Zaidel, EJ | 1 |
| Cui, Y; Guo, L; Jiang, J; Liu, Z; Mu, G; Song, H; Sun, J; Wang, N; Wang, Z; Xiang, J; Xiang, Q; Xie, Q; Yuan, D; Zhang, H; Zhang, Y; Zhao, Z; Zhou, S | 1 |
| Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H | 1 |
| Ansell, J; Freedman, D; Siegal, DM | 1 |
| Matre, NB; McLaughlin, EM; Naik, KD; Rozycki, AJ; Whitson, BA | 1 |
| Albiges, L; Baudin, E; Besse, B; Boileve, A; Ducreux, M; Hadoux, J; Leary, A; Malka, D; Maulard, A; Mir, O; Rieutord, A; Scotté, F | 1 |
| Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H | 1 |
| Gao, JJ; Li, ZW; Wang, B; Xu, HW; Ye, HZ; Zhou, H | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E | 1 |
| Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T | 1 |
| Cohen, D; Lavon, O | 1 |
| Bindler, RJ; Caverley, ZR; Mendelson, S; Soh, P | 1 |
| Carrier, M; Castellucci, LA; Shaw, JR; Siegal, D | 1 |
| Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
| Chen, M; Cheng, YC; Huang, YC; Jhou, MJ; Lu, CJ | 1 |
| Nakano, Y; Sairaku, A | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML | 1 |
| Bessette, LG; Bykov, K; Cervone, A; Kim, DH; Lin, KJ; Mastrorilli, JM; Singer, DE | 1 |
| De Caterina, R; van Es, N; Weitz, JI | 1 |
| Chen, X; Dai, H; Du, X; Gu, P; Guan, C; Huang, N; Huang, X; Li, R; Lin, X; Liu, X; Liu, Y; Lv, M; Wu, T; Xu, W; Zhang, J; Zhang, M; Zhang, W; Zheng, Q; Zhu, Z | 1 |
| Hui, X; Li, J; Li, M; Ma, Y; Tian, J; Wang, Q; Wang, X; Xie, P; Yan, P; Yang, K; Yao, L | 1 |
| Dreijer, A; Lameijer, H; Meijer, K; Mitrovic, D; van den Bemt, P; van Elp, M; van Hulst, M; van Rein, N; van Roon, E; Veeger, N; Visser, L | 1 |
| Hayat, A; Själander, A; Wallvik, J | 1 |
| Ho, LT; Huang, CF; Jeng, JS; Kuo, CH; Lin, SY; Liu, YB; Peng, YF; Tang, SC; Tsai, LK | 1 |
| Alves da Silva, P; Caldeira, D; Pinto, FJ | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Last-Koopmans, S; Mooij, R; Neeteson, M | 1 |
| Blanchon, T; Conte, C; Gosselin, L; Hanslik, T; Lapeyre-Mestre, M; Launay, T; Rossignol, L; Saint-Salvi, B; Sarazin, M; Souty, C; Steichen, O; Turbelin, C; Vilcu, AM | 1 |
| Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L | 1 |
| Hoffman, M; Sarode, R; Welsby, IJ | 1 |
| Bakhtiari, K; Meijers, JCM; Peters, SLM; Zwiers, A | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
| Chu, CL; Dai, JW; Liao, SC; Wang, CH | 1 |
| Bos, MHA; den Exter, PL; Huisman, MV; Klok, FA; Martens, ESL; van der Horst, SFB; van Mens, TE | 1 |
| Brinkmann, M; Diener, HC; Eschenfelder, CC; Gröschel, K; Grosse, GM; Hüsing, A; Kuklik, N; Michalski, D; Nabavi, D; Poli, S; Royl, G; Sparenberg, P; Stang, A; Weimar, C; Weissenborn, K | 1 |
| Chen, J; Ma, F; Xu, W; Zhang, J | 1 |
| Levy, JH; Mamoun, N | 1 |
| Bechler, K; Callahan, A; Shah, N; Xu, Y | 1 |
| Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J | 1 |
| Alt, E; Bessette, LG; Kim, DH; Mahesri, M; Najafzadeh, M; Schneeweiss, S; Shin, H; Wang, SV | 1 |
| An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K | 1 |
| Brunetti, ND; D'Angelo, A; De Gennaro, L; Derosa, G; Gaudio, G; Gavazzoni, M; Maffioli, P; Maggi, A; Pasini, G; Raddino, R; Rizzo, M | 1 |
| Angelini, A; Ballarini, M; Dalmastri, V; Grammatico, F; La Manna, G; Minerva, V; Pizzini, AM; Silingardi, M; Todeschini, P | 1 |
| Baiardi, G; Cafaro, A; Cangemi, G; Caviglia, MC; Mattioli, F; Poeta, MG; Stella, M | 1 |
| Chan, YH; Fong, KY; Lip, GYH; Tan, VH; Yeo, C | 1 |
| Chilbert, MR; Goriacko, P; Jacobs, D; Saber, M; Sinnet, M; Woodruff, AE | 1 |
| Cera, M; Comi, G; Cozzani, G; Della Bella, P; Gaspardone, C; Godino, C; Leo, G; Maisano, F; Margonato, A; Mattiello, P; Melillo, F; Montorfano, M; Nemola, G; Parlati, AL; Russi, A; Salerno, A; Sparasci, FM; Tresoldi, M; Vetrugno, L; Zangrillo, A | 1 |
| Akerman, M; Chin-Hon, J; Davenport, L; Hindenburg, A; Huang, J | 1 |
| Chen, Y; Huang, K; Wu, M; Xia, H; Yu, S; Yu, W; Zhou, H | 1 |
| Ceulemans, A; Heuts, S; Kuiper, GJAJM; Maesen, B; Maessen, JG; Milojevic, M; Olie, RH; Schreiber, JU; Ten Cate, H; van Varik, BJ | 1 |
| Berry, SD; Daiello, LA; Hayes, KN; Kiel, DP; Kim, DH; Lee, Y; Zhang, T; Zullo, AR | 1 |
| Huang, KC; Lee, JK; Lin, DS; Lin, TT; Lo, HY | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kiss, RG; Kleine, E; Lip, GYH; Navarro Estrada, JL; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM | 1 |
| Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA | 1 |
| Butcher, K; Fanikos, J; França, LR; Gruenenfelder, F; Kermer, P; Lane, DA; Murwin, D; Reilly, PA; Tartakovsky, I; Wowern, FV | 1 |
| Alasheev, A; Canhão, P; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Frässdorf, M; Huisman, H; Karpov, D; Kobayashi, A; Nagel, S; Posthuma, L; Reilly, P; Roriz, JM | 1 |
| Bao, HH; Cheng, XS; Hu, LH; Huang, X; Li, JX; Wang, T; Wen, MH; Wu, QH; Wu, YQ; You, CJ; Zhou, W; Zhu, LJ | 1 |
| Casajuana, M; Giner-Soriano, M; Morros, R; Roso-Llorach, A; Vedia, C | 1 |
| Eikelboom, JW; Elsaesser, A; Glund, S; Hylek, EM; Pollack, CV; Reilly, P; van Ryn, J; Weitz, JI | 1 |
| Elsaesser, A; Glund, S; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; van Ryn, J; Weitz, JI | 1 |
| Borrie, A; Carter, J; Dookia, R; Wheeler, M | 1 |
| Blin, P; de Pouvourville, G; Karam, P | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; França, LR; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Mazurek, M; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Bartels, DB; Gopalakrishnan, C; Gurusamy, VK; Huybrechts, KF; Landon, J; Schneeweiss, S; Zint, K | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Drabik, L; Potpara, T; Undas, A | 2 |
| Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 2 |
| Bhatt, DL; Cannon, CP; Ducrocq, G; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Boissier, E; Bourcier, R; Dargazanli, C; Desal, H; Gory, B; Kyheng, M; L'Allinec, V; Labreuche, J; Lapergue, B; Mazighi, M; Roy, M; Sibon, I | 1 |
| Chaiyakunapruk, N; Dilokthornsakul, P; Hollingworth, W; Jahan, NK; Kongpakwattana, K; Lai, NM; Nathisuwan, S; Ng, SS | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Buda, S; Degli Esposti, L; Perrone, V; Piovaccari, G; Saragoni, S | 1 |
| Huang, Y; Liang, H; Rong, G; Wang, H; Wang, L | 1 |
| Alvarez, P; Asleh, R; Briasoulis, A; Chrischilles, E; Gao, Y; Inampudi, C; Leira, EC; Vaughan-Sarrazin, M | 1 |
| Bernstein, RA; Clark, CL; Douketis, J; Fanikos, J; Fermann, GJ; Fiore, GJ; Frost, A; Jahromi, B; Johnson, C; Merli, G; Peacock, WF; Pollack, CV; Silber, S; Villines, TC | 1 |
| de Boer, A; Gardarsdottir, H; Maitland-van der Zee, AH; Souverein, PC; van den Ham, HA; Zhang, Y | 1 |
| Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Taniguchi, A; Uchiyama, S; Yamashita, T; Yasaka, M | 2 |
| Bochkov, P; Fomin, V; Gurinovich, O; Kogay, V; Krainyaya, A; Krupenin, P; Listratov, A; Napalkov, D; Shevchenko, R; Skripka, A; Sokolova, A; Sychev, D | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Benczur, B; Bergler-Klein, J; Ciernik, M; Gotcheva, N; Medvedchikov, A; Napalkov, D; Põder, P; Simic, D; Skride, A; Tang, W; Trusz-Gluza, M; Vesely, J; Vinereanu, D; Vishnepolsky, T; Vrabec, M | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Ashley, J; Badve, SV; Battistella, M; Bota, S; Garg, AX; Harel, Z; Jun, M; Manuel, D; Mavrakanas, T; McArthur, E; Molnar, AO; Rhodes, E; Sood, MM; Tanuseputro, P; Wells, P | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Brooks, MM; Glynn, NW; Hernandez, I; Saba, S; Yang, L; Zhang, Y | 1 |
| Han, X; Ma, L; Nie, X; Peng, L; Wang, J; Zan, X; Zheng, N | 1 |
| Balusson, F; Bouget, J; Lacut, K; Maignan, M; Nowak, E; Oger, E; Pavageau, L; Roy, PM; Scailteux, LM | 1 |
| Adar, A; Cakan, F; Onalan, O | 1 |
| Chaudhary, R; Garg, J; McBane, RD; Murad, MH; Pagali, S; Wysokinski, WE | 1 |
| Douketis, J; Kaplovitch, E; Shaw, JR | 1 |
| Carrier, M; Clark, EG; Garg, AX; Harel, Z; Hill, K; Hundemer, GL; Knoll, G; McArthur, E; Rhodes, E; Sood, MM; Sucha, E | 1 |
| Chen, L; Li, N; Liu, W; Qi, F; Wang, N; Xu, G; Zhu, L | 1 |
| Cipriano, A; Parollo, M; Santini, M; Taurino, E; Venturi, E | 1 |
| Lorenz, KW; Schäfer, R | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Le, T; Pasciolla, S; Wright, K; Zizza, LF | 1 |
| Aakjaer, M; Andersen, M; De Bruin, ML; Gardarsdottir, H; Heeke, A; Huerta, C; Klungel, OH; León-Muñoz, LM; Merino, EM; Montero, D; Rottenkolber, M; Schmiedl, S; Souverein, PC; van den Ham, HA | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Buyukdere, H; Carrier, M; Castellucci, LA; Chakraborty, S; Dowlatshahi, D; Shaw, JR; Tokessy, M | 1 |
| Darius, H | 3 |
| Cao, ZC; Dong, Y; Huang, ZC; Jia, HY; Li, CQ; Liu, TL; Liu, XY; Sun, JJ | 1 |
| Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 1 |
| Cui, Y; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S | 1 |
| Caprini, JA; Clark, NP; Douketis, J; Kaplovitch, E; Li, N; MacDougall, K; Schulman, S; Spyropoulos, AC; Tafur, AJ | 1 |
| Bouchard, J; Brindamour, D; Charbonney, E; Dobrescu, MA; Dupuis, S; Flynn, F; Richard, G; Williamson, D | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Bao, H; Cheng, X; Hu, L; Li, M; Wang, T; Yu, Y; Zhou, W; Zhu, L | 1 |
| Amano, Y; Fujishiro, H; Harada, H; Hayasaka, K; Iwaki, T; Katsuyama, Y; Kushiyama, Y; Maeda, G; Miyaoka, Y; Murakami, D; Nakahara, R; Ujihara, T; Yuki, T | 1 |
| Bernier, M; Drici, MD; Lancrerot, SL; Lavrut, T; Parassol, N; Rocher, F; Viotti, J | 1 |
| Haas, S; Patti, G | 1 |
| Brown, JD; Cristofoletti, R; Farhan, N; George, JM; Gordon, LA; Hadigan, C; Kim, S; Kumar, P; Lingineni, K; Penzak, S; Schmidt, S | 1 |
| Davis, KA; Valanejad, SM | 1 |
| Harano, T; Morrell, MR; Rivosecchi, RM; Sanchez, PG | 1 |
| Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B | 1 |
| Ali, H; Balla, C; Bonitta, G; Briani, M; Cappato, R; Chiarito, M; Furlanello, F; Giustozzi, M; Lodigiani, C; Lupo, P; Riva, L; Stefanini, G | 1 |
| Bertoletti, L; Cucherat, M; Durieu, I; Grange, C; Grenet, G; Gueyffier, F; Kilo, R; Laporte, S; Lega, JC; Mainbourg, S; Mismetti, P; Nony, P; Provencher, S | 1 |
| Ji, Q; Li, X; Lv, Q; Wang, Z; Xu, Q; Zhang, C | 1 |
| Chan, N; Eikelboom, JW; Sobieraj-Teague, M | 1 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Bhatt, DL; Cannon, CP; Costa, F; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Valgimigli, M | 1 |
| Chen, X; Fan, Y; Fu, Z; Liu, M; Ni, L; Sun, D; Zhao, Z | 1 |
| Beasley, M; Brown, TM; Davis, BH; Dillon, C; Limdi, NA; McElderry, T; Narayan, R; Nolin, TD; Sangha, R | 1 |
| Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Jiang, YR; Liao, JN; Tsai, CT | 1 |
| Basu, S; Brown, JD; Cristofoletti, R; Fang, LL; Farhan, N; Jiang, S; Kim, S; Lesko, LJ; Lingineni, K; Schmidt, S | 1 |
| Gorr, HS; Hung, E; Lu, LY | 1 |
| Lorenzoni, V; Pirri, S; Turchetti, G | 1 |
| Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS | 1 |
| Bose, G; Coutinho, J; Dowlatshahi, D; Fergusson, DA; Graveline, J; Le Gal, G; Mendonça, M; Nagel, S; Shorr, R; Viana-Baptista, M; Yogendrakumar, V | 1 |
| Côté, R; Dorais, M; Martel, MJ; Perreault, S; Qazi, JZ; Schnitzer, ME | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Altay, S; Aşkın, L; Beşli, F; Çakmak, HA; Canpolat, U; Gedikli, Ö; Pehlivanoğlu, S; Şahin, M; Sinan, ÜY; Ünlü, S; Yanık, A | 1 |
| Chen, HY; Chou, KJ; Huang, CW; Lee, PT; Lin, PC; Ou, SH; Su, YC | 1 |
| Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S | 1 |
| de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD | 1 |
| Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL | 1 |
| Gilbert, BW; Ott, MJ; Philip, GJ | 1 |
| Pos, L | 1 |
| Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
| Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Diener, HC; Dubner, SJ; Hall, C; Halperin, JL; Huisman, MV; Kalejs, O; Lip, GYH; Lyrer, P; Ma, CS; Rothman, KJ; Teutsch, C; van der Wall, SJ; Zhai, D; Zint, K | 1 |
| Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
| Bolek, T; Galajda, P; Kamenišťáková, A; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS | 1 |
| Beyer-Westendorf, J; Birschmann, I; Greinacher, A; Grottke, O; Herrmann, E; Konstantinides, S; Kuhn, J; Lindau, S; Lindhoff-Last, E; Lucks, J; Meybohm, P; Nowak-Göttl, U; Schellong, S; Sümnig, A; von Heymann, C; Zydek, B | 1 |
| Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A | 1 |
| Jiang, J; Li, W; Wang, M; Wang, S; Wang, X; Wu, T; Xie, J; Xue, E; Zhan, S; Zheng, H; Zhou, R | 1 |
| Chen, CY; Chu, CC; Huang, YL | 1 |
| Chan, NC; Eikelboom, JW; Xu, K | 1 |
| Ageno, W; Barco, S; Bouvaist, H; Brodmann, M; Couturaud, F; Cuccia, C; Dellas, C; Dimopoulos, K; Duerschmied, D; Empen, K; Faggiano, P; Ferrari, E; Galiè, N; Galvani, M; Ghuysen, A; Giannakoulas, G; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Mavromanoli, AC; Meneveau, N; Meyer, G; Münzel, T; Palazzini, M; Petris, AO; Piovaccari, G; Salvi, A; Schellong, S; Schmidt, KH; Schmidtmann, I; Toenges, G; Verschuren, F | 1 |
| Ader, J; Desai, NR; Jones, PG; Reinhardt, SW; Spertus, JA; Tang, Y | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Biss, B; Brouwer, MA; Calkins, H; Gerstenfeld, EP; Grimaldi, M; Guiver, K; Hohnloser, SH; Nordaby, M; Okumura, K; Schilling, R; Serota, H; Verma, A; Willems, S | 1 |
| Banares, L; Dager, WE | 1 |
| Birnie, DH; Connolly, SJ; Coutu, B; Douketis, J; Essebag, V; Ezekowitz, M; Healey, JS; Hohnloser, SH; Lip, GYH; Moriarty, A; Oldgren, J; Parkash, R; Proietti, R; Wang, J | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Schulman, S | 2 |
| Bestle, M; Boesby, L; Poulsen, CG | 1 |
| Bhave, PD; Chrischilles, E; Girotra, S; Giudici, M; Hodgson-Zingman, D; Mazur, A; Palamaner Subash Shantha, G; Vaughan Sarrazin, MS | 1 |
| Albaladejo, P; Bellamy, L; Bosson, JL; David, JS; de Maistre, E; Gruel, Y; Kauffmann, S; Mémier, V; Pernod, G; Romegoux, P; Samama, CM; Sié, P; Suchon, P; Thoret, S; Viallon, A | 1 |
| Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; Stoppe, C; Ten Cate, H; van Ryn, J | 1 |
| Ay, C; Domanovits, H; Levy, JH; Sengoelge, G; Simon, A; Spiel, AO | 1 |
| Bo, M; Di Minno, G; Di Pasquale, G; Genovesi, S; Molteni, M; Toni, D; Verdecchia, P | 1 |
| Grottke, O; Hofer, S; Lier, H | 1 |
| Gradišek, P; Krevel, B; Mavri, A; Mijovski, MB; Stecher, A; Vene, N | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Rogers, JG | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Cei, M; Dentali, F; Giorgi-Pierfranceschi, M; Mastroiacovo, D; Mumoli, N; Tamborini-Permunian, E; Vitale, J | 1 |
| Churilov, L; Hardidge, AJ; Suen, K; Westh, RN | 1 |
| Guenzer, JR; Meltzer, J | 1 |
| Alamiri, K; Novak, JE; Yee, J | 1 |
| Asvestas, D; Bazoukis, G; Efremidis, M; Efremidis, T; Georgopoulos, S; Karamichalakis, N; Kolokathis, AM; Letsas, KP; Rokiza, A; Sakellaropoulou, A; Saplaouras, A; Sideris, A; Vlachos, K | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Gupta, K; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Trocio, J; You, M | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F | 1 |
| Aiello, A; Aspromonte, N; Colivicchi, F; Di Fusco, SA; Santini, M; Tubaro, M | 1 |
| Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
| Andreozzi, GM; Bignamini, AA; Kuca, P; Tomkowski, W | 1 |
| Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L | 1 |
| Arora, P; Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Cheong, JS; Chung, JY; Kang, HG; Lee, SJ | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Køber, L; Lamberts, M; Olesen, JB; Staerk, L; Vinding, NE | 1 |
| Gimbar, RP; Jarrett, JB | 1 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Hu, SJ; Wu, T; Xu, WW | 1 |
| Bernstein, RA; Dubiel, R; Eikelboom, JW; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Royle, G; Sellke, FW; Stangier, J; Steiner, T; van Ryn, J; Verhamme, P; Wang, B; Weitz, JI; Young, L | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Dager, WE; Lee, JA; Steele, AP | 1 |
| Lip, GYH; Makaritsis, K; Michel, P; Ntaios, G; Papavasileiou, V; Vemmos, K | 1 |
| Dincq, AS; Dogné, JM; Douxfils, J; Larock, AS; Lessire, S; Mullier, F; Vornicu, O | 1 |
| Gersh, BJ; Hargraves, I; Montori, VM; Noseworthy, PA; Shah, ND; Yao, X | 1 |
| Cossey, TC; Grotta, JC; Reddy, ST; Savitz, SI | 1 |
| Chan, EW; Lau, WCY; Leung, WK; Li, X; Lip, GYH; Man, KKC; Siu, CW; Wong, ICK | 1 |
| Valent, F | 1 |
| Cao, Q; Jacobs, MS; Jansman, FGA; Postma, MJ; Tieleman, RG; van Hulst, M; van Leent, MWJ | 1 |
| Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Davis, DO; Davis, KA | 1 |
| Golaszewski, SM; Pikija, S; Sebastian Mutzenbach, J; Sellner, J; Sztriha, LK | 1 |
| Bézie, Y; Bourguignon, S; Chevalier, D; Jamet, N; Paubel, P; Thivilliers, AP | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Curtice, T; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Luo, X; Mardekian, J; Menges, B; Trocio, J | 1 |
| Abarca, J; Adeboyeje, G; Barron, JJ; Crawford, G; Redberg, R; Rosenberg, A; Sylwestrzak, G; White, J | 1 |
| Izumi, N; Katada, J; Kohsaka, S; Murata, T; Terayama, Y; Wang, F | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Stoppe, C; Ten Cate, H | 1 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 1 |
| Alonso, A; Bengtson, LGS; Chamberlain, AM; Chen, LY; Lutsey, PL; MacLehose, RF; Norby, FL; Rapson, I | 1 |
| Carley, B; Draper, E; Griesbach, S; Krueger, K; Larson, T; Parkhurst, B | 1 |
| Agnelli, G; Becattini, C; Giustozzi, M; Verso, M | 1 |
| Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I | 1 |
| Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Calculli, G; Carbonara, R; Carbonara, S; Cecere, A; Ciccone, MM; Cortese, AM; Cortese, F; De Vito, F; Gesualdo, M; Zito, A | 1 |
| Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M | 1 |
| Collings, SL; Evans, D; Hack, G; Johnson, ME; Lefèvre, C; Maguire, A; Stynes, G | 1 |
| Alla, F; Billionnet, C; Gagne, JJ; Maura, G; Pariente, A | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Lane, DA; Oldgren, J; Proietti, M; Roldan, V; Wallentin, L; Yusuf, S | 1 |
| Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E | 1 |
| Ali, M; Gunasekaran, K; Kaatz, S; Lavender, R; Mahan, CE; Nakhle, A; Paje, DG | 1 |
| Basto, AN; Fewel, NP; Stock, EM; Ta, M; Vo, K | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Chen, HM; Chou, PC; Chua, SK; Lee, CW; Li, YH; Liao, PC; Lin, HJ; Lin, MJ; Tsai, LK; Yang, YP; Yeh, JT | 1 |
| Cheetham, TC; Gagne, JJ; Go, AS; Goulding, MR; Graham, DJ; Houstoun, M; Izem, R; Mott, K; Reichman, ME; Singer, DE; Southworth, MR; Sung, SH; Toh, S; Zhang, R | 1 |
| Beshir, SA; Chee, KH; Lo, YL; Sim, S; Yap, LB | 1 |
| Eek, AK; Granas, AG; Øie, E | 1 |
| Arshad, A; Kaluski, E; Khan, SU; Nasir, F; Riaz, IB; Talluri, S | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schüler, E; Schulman, S | 1 |
| Albisetti, M; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, JML; Harper, R; Huang, F; Maas, H; Mitchell, LG; Nurmeev, I; Picard, AC; Tartakovsky, I | 1 |
| Chan, NC; Weitz, JI | 1 |
| Anderson, JM; Arnold, DM; Bates, SM; Blostein, M; Caprini, JA; Carrier, M; Clark, NP; Coppens, M; Dentali, F; Douketis, JD; Duncan, J; Gross, PL; Kassis, J; Kowalski, S; Le Gal, G; Le Templier, G; Lee, AY; Li, N; MacKay, E; Schulman, S; Shah, V; Shivakumar, S; Solymoss, S; Spencer, FA; Spyropoulos, AC; Syed, S; Tafur, AJ; Thiele, T; Vanassche, T; Wu, C; Yeo, E | 1 |
| Ageno, W; Barco, S; Binder, H; Brenner, B; Duerschmied, D; Empen, K; Faggiano, P; Ficker, JH; Galiè, N; Ghuysen, A; Held, M; Heydenreich, N; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Meyer, G; Münzel, T; Petris, A; Pruszczyk, P; Quitzau, K; Schellong, S; Schmidt, KH; Stefanovic, BS; Verschuren, F; Wolf-Puetz, A | 1 |
| Singer, AJ; Wilson, S | 1 |
| Abdul-Rahim, AH; Acampa, M; Acciarresi, M; Ageno, W; Agnelli, G; Alberti, A; Athanasakis, G; Bandini, F; Becattini, C; Bellesini, M; Bono, G; Bovi, P; Cappellari, M; Carletti, M; Carolei, A; Caso, V; Chiti, A; Chondrogianni, M; Ciccone, A; Cimini, LA; Colombo, G; Consoli, D; Corea, F; D'Amore, C; De Lodovici, ML; Denti, L; Falocci, N; Flomin, Y; Furie, KL; Galati, F; Gialdini, G; Giannini, N; Giorli, E; Giuntini, M; Gourbali, V; Guideri, F; Karagkiozi, E; Karapanayiotides, T; Kargiotis, O; Lanari, A; Lees, KR; Letteri, F; Liantinioti, C; Lorenzini, G; Lotti, EM; Maccarrone, M; Maimone Baronello, M; Makaritsis, K; Mancuso, M; Marcheselli, S; Martini, G; Masotti, L; Monaco, S; Mosconi, MG; Mumoli, N; Ntaios, G; Orlandi, G; Paciaroni, M; Padovani, A; Pezzini, A; Poli, L; Putaala, J; Sacco, S; Scoditti, U; Silvestrelli, G; Sohn, SI; Soloperto, R; Tadi, P; Tassi, R; Tassinari, T; Tatlisumak, T; Tiseo, C; Tomppo, L; Toni, D; Tsivgoulis, G; Vadikolias, K; Vannucchi, V; Venti, M; Yaghi, S; Zedde, M | 1 |
| Ahn, Y; Cho, JG; Cho, JY; Hong, YJ; Hyun, DY; Jeong, MH; Kim, JH; Kim, KH; Kim, MC; Kim, Y; Lee, KH; Lee, N; Oh, SS; Park, HJ; Park, HW; Park, JC; Sim, DS; Won, J; Yoon, HJ; Yoon, NS | 1 |
| Raco, DL | 1 |
| D'Onofrio, A; Golino, P; Nigro, G; Papa, AA; Rago, A; Russo, V | 1 |
| Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N | 1 |
| Levanov, AN; Sinitsina, II; Sychev, DA; Tsomaya, IV; Vardanyan, AV | 1 |
| Elder, J; Fu, AC; Jain, R; Lim, J; Sander, SD; Tan, H; Wang, C | 1 |
| Berrazueta Fernández, JR; de Tapia Majado, B; Sanlés González, I | 1 |
| Lindeman, E | 1 |
| Steurer, J | 3 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Boehlen, F; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Han, F; He, H; Ke, B; Li, X; Li, Y; Zeng, Y | 1 |
| Balsam, P; Bednarski, J; Filipiak, KJ; Grabowski, M; Kowalczuk, A; Kołtowski, Ł; Lodziński, P; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Ogińska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Basic, E; Hohmann, C; Hohnloser, SH; Nabauer, M | 1 |
| Jesus, PAP; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S | 1 |
| Atar, D; Ghanima, W; König, MSS; Raouf, N; Risnes, K; Rutherford, OW | 1 |
| Choudhry, NK; Gagne, JJ; Najafzadeh, M; Schneeweiss, S; Wang, SV | 1 |
| Allehyani, MF; Hayes, BD; Rosenbaum, SB; Vilke, GM; Winters, ME | 1 |
| Gaussem, P; Gay, J; Gendron, N; Lemoine, M; Lillo-Le-Louet, A; Smadja, DM | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Angelillo-Scherrer, A; Cuker, A; Eberle, B; Erdoes, G; Exadaktylos, AK; Nagler, M; Sauter, TC; Thiele, T; Wuillemin, WA | 1 |
| Adeboyeje, G; Barron, JJ; Charlton, B; Grady, D; Redberg, RF; Shin, J | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Gheysens, O; Goffin, KE; Hoylaerts, MF; Jacquemin, M; Liesenborghs, L; Peerlinck, K; Peetermans, M; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P; Wijngaerden, EV | 1 |
| Leow, AS; Loh, JP; Sia, CH; Tan, BY | 1 |
| Akman, N; Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Schöchl, H; Schütt, K; Stoppe, C | 1 |
| Dülgeroglu, J; Schmidt, D | 1 |
| Kamble, S; Kawabata, H; Lip, GYH; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Garzon, J; Jaramillo, L; Mendoza, L; Mendoza-Sanchez, J; Quiroga, A; Rangel, L; Silva, F | 1 |
| Aoshima, M; Nakashima, K; Nemoto, M; Shiroshita, A; Tanaka, Y; Tateishi, A | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Adelmeijer, J; Bernal, W; Bos, S; Fisher, C; Kleiss, S; Lisman, T; Patel, VC; Shawcross, DL; Singanayagam, A; Stoy, SH | 1 |
| Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M | 1 |
| Ageno, W; Antonucci, E; Beyer-Westendorf, J; Morandini, R; Paciaroni, M; Palareti, G; Pengo, V; Poli, D; Righini, M; Sivera, P; Testa, S; Verhamme, P | 1 |
| Kaiser, T; Metze, M; Peschka, A; Petros, S; Pfrepper, C; Weidhase, L | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Durand, M; Johnson, S; Matteau, A; Sinyavskaya, L | 1 |
| Brennan, Y; Curnow, J; Favaloro, EJ; Keenan, H; Pasalic, L | 1 |
| Cavallari, I; De Caterina, R; Hanon, O; Patti, G | 1 |
| Basalo, MC; Ferrero-Martínez, AI; Gómez-Quintanilla, A; Guitián, A; Montero-Magan, M; Olcoz-Chiva, MT; Paredes-Galán, E; Rodríguez-Artalejo, F; Rodríguez-Pascual, C; Sharma, J; Torres-Torres, I; Vilches-Moraga, A | 1 |
| Barden, S; Campbell, T; Condliffe, R; Connolly, V; Davies, CWH; Donaldson, J; Everett, B; Free, C; Horner, D; Howard, LSGE; Hunter, L; Kaler, J; Nelson-Piercy, C; O-Dowd, E; Patel, R; Preston, W; Sheares, K | 1 |
| Bangdiwala, SI; Berwanger, O; Biccard, BM; Botto, F; Chaudhry, NK; Connolly, SJ; de Nadal, M; Devereaux, PJ; Duceppe, E; Eikelboom, JW; Erb, J; Franzosi, MG; Guyatt, G; Hoeft, A; Iglesias, PP; Kearon, C; Magloire, P; Mayosi, B; Meyhoff, CS; Neary, J; Pettit, S; Rahate, PV; Rao, M; Rao-Melacini, P; Rodseth, R; Sessler, DI; Sharma, M; Srinathan, SK; Szczeklik, W; Tandon, V; Villar, JC; Vincent, J; Xavier, D; Yusuf, S | 1 |
| Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE | 1 |
| Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H | 1 |
| Bohn, J; Cosgrove, A; Desai, RJ; Gagne, JJ; Jin, Y; Karami, S; Kennedy, A; Kim, C; Kim, J; Major, JM; Niman, A; Ouellet-Hellstrom, R; Toh, S; Wang, SV; Wyss, R | 1 |
| Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM | 1 |
| Coupland, C; Hill, T; Hippisley-Cox, J; Vinogradova, Y | 1 |
| Alviz, I; Avendano, R; Cerna, L; Cerrud-Rodriguez, RC; Di Biase, L; Diaz, JC; Grupposo, V; Kirchhof, P; Kumar, S; Michaud, GF; Natale, A; Romero, J; Taveras, J | 1 |
| Chrapek, M; Janion-Sadowska, A; Papuga-Szela, E; Undas, A; Łukaszuk, R | 1 |
| Karakas-Torgut, A; Mo, Y; Pham, AQ | 1 |
| Azboy, I; Groff, H; Parvizi, J | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Barbay, V; Billoir, P; Boyer, D; Chrétien, MH; Fresel, M; Girault, C; Grangé, S; Le Cam Duchez, V | 1 |
| Gouin-Thibault, I; Gris, JC | 1 |
| Levy, JH | 4 |
| Bertazzoni, G; Cipollone, L; De Michele, M; Falcou, A; Letteri, F; Spagnolello, O; Toni, D | 1 |
| Ahuja, T; Green, D; Raco, V | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M | 1 |
| Domanovits, H; Frossard, M; Gremmel, T; Niessner, A; Pabinger, I; Sengölge, G; Steinlechner, B; Sycha, T; Wolzt, M | 1 |
| Kido, K; Ngorsuraches, S | 1 |
| Bakkehøi, G; Eek, AK; Stenberg-Nilsen, H; Strøm, BO | 1 |
| Padrini, R | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Aljohani, MM; Alsager, OA; Chinnappan, R; Cialla-May, D; Eissa, S; Popp, J; Weber, K; Zourob, M | 1 |
| Sheikh-Taha, M | 2 |
| Franchino-Elder, J; Gilligan, AM; Henriques, C; Sainski-Nguyen, A; Sander, S; Smith, DM; Song, X; Wang, C; Wilson, K | 1 |
| Agnelli, G; Aita, A; Angeli, F; Becattini, C; Cavallini, C; Conti, S; Giustozzi, M; Molini, G; Turturiello, D; Vedovati, MC; Verdecchia, P | 1 |
| Bates, ER | 1 |
| Lip, GYH | 1 |
| Alings, AMW; Huisman, MV; Klok, FA; Kruip, MJHA; Meijer, K; Simmers, TA; Te Boome, LCJ; Tieleman, R; van den Bemt, B; van der Wall, SJ; van Rein, N; Westerweel, PE | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Ji, Q; Li, X; Lv, Q; Wang, Z; Xu, Q | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Dei, A; Grifoni, E; Landini, G; Masotti, L; Moroni, F; Panigada, G; Spolveri, S; Vannucchi, V | 1 |
| Alcusky, M; Fisher, M; Goldberg, RJ; Hume, AL; Lapane, KL; McManus, DD; Tjia, J | 1 |
| Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N | 1 |
| George, S; Lewis, V; Taburyanskaya, M | 1 |
| Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB | 1 |
| Dager, WE; Nishijima, DK; Roberts, AJ | 1 |
| Fanaroff, AC; Ohman, EM | 1 |
| Hirakawa, T; Ishida, K; Koretsune, Y; Kuroki, D; Ono, Y; Sumida, T; Urushihara, H; Yamashita, T; Yasaka, M | 1 |
| Ahmad, A; Evans, A; Oh, K; Petrini, M; Rush, T; Schwartzman, E; Tang, W; Thompson, D; Villines, TC | 1 |
| Ackery, A; Chaudhry, H; Mahamad, S; McFarlan, A; Nisenbaum, R; Rizoli, S; Sholzberg, M | 1 |
| Själander, A; Själander, S | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Schöchl, H | 1 |
| Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT | 1 |
| Gouin-Thibault, I; Jourdi, G; Le Bonniec, B | 1 |
| Arakawa, K; Endo, T; Fukui, K; Himeno, H; Ishikawa, T; Kikuchi, S; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okuda, J; Sakamaki, K; Sawada, R; Shigemasa, T; Shimizu, M; Sugano, T; Takamura, T; Tamura, K; Tsukahara, K; Tsunematsu, T | 1 |
| Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A | 1 |
| Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S | 1 |
| Huang, Y; Que, D; Wang, L; Wu, S; Xie, S; Xu, Y; Yau, TO | 1 |
| Amiya, R; Higuchi, Y; Hirata, A; Hirayama, A; Kobayashi, T; Sakata, Y; Sotomi, Y | 1 |
| Gressenberger, P | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Young, M | 1 |
| Chao, AC; Chen, CF; Chou, PS; Ho, BL; Hu, HH; Lin, RT; Lin, SF; Lin, YJ | 1 |
| Bartels, DB; Franklin, JM; Gopalakrishnan, C; Huybrechts, KF; Kulldorff, M; Schneeweiss, S; Zint, K | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Jesus, P; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG; Souza, IFB | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Cha, MJ; Choi, EK; Kim, HM; Kwon, JM; Lee, SY; Oh, S; Park, CS | 1 |
| Baranchuk, A; Corbalán, R; Enríquez, A | 1 |
| Attena, E; Calabrò, P; Crisci, M; D'Onofrio, A; Golino, P; Nigro, G; Papa, AA; Proietti, R; Rago, A; Rainone, C; Russo, V | 1 |
| Basic, E; Hohnloser, SH; Nabauer, M | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Aonuma, K; Goya, M; Harada, T; Hirao, K; Kihara, Y; Nakahara, S; Nakano, Y; Nogami, A; Nuruki, N; Origasa, H; Otani, R; Sekiguchi, Y; Yoshida, K; Yoshida, Y | 1 |
| Arbel, M; Ayata, C; Bacskai, BJ; Böhm, M; Boulouis, G; Endres, M; Fischer, P; Frosch, MP; Greenberg, SM; Qin, T; Schlunk, F; Tamim, I | 1 |
| Antonucci, E; Cosmi, B; Dellanoce, C; Legnani, C; Morandini, R; Palareti, G; Paoletti, O; Pengo, V; Poli, D; Testa, R; Testa, S; Tripodi, A | 1 |
| Kasper, EM; Lu, VM; Phan, K; Rao, PJ; Sharma, SV | 1 |
| Benarousse, G; Crisan, O; Elalamy, I; Gruenenfelder, F; Tazarourte, K | 1 |
| Medlicott, NJ; Reith, D; Simpson, BH; Smith, A | 1 |
| Alings, M; Connolly, SJ; Dorresteijn, JAN; Eikelboom, JW; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; van der Leeuw, J; Visseren, FLJ | 1 |
| Caughey, G; Duszynski, K; Kalisch Ellett, LM; Kerr, M; Pratt, NL; Ramsay, E; Roughead, EE; Shakib, S | 1 |
| Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Husová, L | 1 |
| Imberti, D; Mastroiacovo, D; Pomero, F | 1 |
| Dina, O; Gupta, K; Keshishian, A; Mardekian, J; Nadkarni, A; Shank, TC; Trocio, J; Zhang, Q | 1 |
| Cha, MJ; Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Ambrosio, G; Carluccio, E; Giannandrea, D; Mengoni, A | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Cornutt, D; Desai, NR | 1 |
| Hinotsu, S; Kano, MR; Kitamura, Y; Koyama, T; Miller, MW; Ogawa, A; Ohshima, A; Sendo, T; Tanaka, HY; Zamami, Y | 1 |
| López-López, JA; Thom, H; Welton, NJ | 1 |
| Camm, AJ | 1 |
| Dieterich, M; Dietrich, D; Feil, K; Feuerecker, R; Jandl, M; Kellert, L; Klein, M; Küpper, C; Lücking, M; Marziniak, M; Poppert, H; Thanbichler, F; Topka, H; Wunderlich, S; Zerkaulen, I | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S | 1 |
| Alikhan, R; Baglin, T; Benson, G; Green, L; Keeling, D; Marshall, S; Patel, R; Pavord, S; Rayment, R; Rose, P; Tait, C | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Axelsson, T; Connolly, S; Eikelboom, J; Eriksson, N; Ezekowitz, MD; Haertter, S; Lehr, T; Oldgren, J; Paré, G; Reilly, P; Siegbahn, A; Syvanen, AC; Wadelius, C; Wadelius, M; Wallentin, L; Yusuf, S; Zimdahl-Gelling, H | 1 |
| Dager, WE; Gosselin, RC; Roberts, AJ | 1 |
| Reichman, ME; Southworth, MR; Unger, EF | 1 |
| Berger, R; Chase, M; Ganetsky, M; Salhanick, SD | 1 |
| Baumann, MR; Cabral, KP; Croft, PE; Delaney, MC; Gibbs, MA; Strout, TD | 1 |
| Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA | 1 |
| Christory, F; Connolly, SJ; Dan, GA; Hatala, R; Huber, K; Kher, A; Kiss, RG; Klun, NV; Meier, B; Merkely, B; Pieske, B; Potpara, T; Stępińska, J; Vinereanu, D; Widimský, P | 1 |
| Attia, JR; Pearce, R | 1 |
| Eikelboom, JW; Hankey, GJ | 1 |
| Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Harris, K; Mant, J | 1 |
| Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
| Yasaka, M | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y | 1 |
| Lal, Y; Van Heukelom, J | 2 |
| Bogdanov, A; Dalton, E; Sandhu, PS; Wilson, C | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Butler, J; Chunilal, S; Hapgood, G; Malan, E; Tran, H | 1 |
| Pollack, CV | 4 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Finsterer, J; Stöllberger, C | 1 |
| Diener, HC | 1 |
| Douketis, J; Lang, ES; Lazo-Langner, A | 1 |
| Crowther, MA; Daw, HA; Fawole, A | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Eikelboom, JW; Robinson, M; Schulman, S; Shortt, B | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Ellis, CR; Kaiser, DW | 1 |
| Djalali, S | 1 |
| Eikelboom, JW; Weitz, JI | 2 |
| Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T | 1 |
| Baumann Kreuziger, LM; Reding, MT | 1 |
| Alvrtsyan, H; Francis, K; Matchar, D; Miyasato, G; Rao, Y; Sanchez, H; Sander, S; Siu, K; Walker, D; Yu, C; Zalesak, M | 1 |
| Baglin, T | 1 |
| Avorn, J | 1 |
| Majeed, A; Schulman, S | 1 |
| Camm, AJ; Hohnloser, SH | 1 |
| Bahmaid, RA; Bin Abdulhak, AA; Garbati, MA; Khan, AR; Sanders, SU; Spertus, JA; Steigerwalt, KE; Tleyjeh, IM; Wimmer, AP | 1 |
| Bischof, EF; Cheungpasitporn, W; Ratanapo, S; Srivali, N; Ungprasert, P | 1 |
| Rosenfeld, JV; Schaerf, NB; Thomas, PA | 1 |
| Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU | 1 |
| Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H | 1 |
| Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Conway, SE; Schaeffer, S | 1 |
| Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S | 1 |
| Chandler, WL | 1 |
| Blum, J; Carreiro, S; Hack, JB | 1 |
| Waks, JW; Zimetbaum, PJ | 1 |
| Borobia, AM; Casado, MS; Díaz, MQ; Fabra, S; García-Erce, JA; Núñez, MA; Samama, CM; Virto, AM | 1 |
| Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB | 1 |
| DeMuro, JP | 1 |
| Gulseth, M; Hellwig, T | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Okada, Y; Yasaka, M | 1 |
| Conway, SE; Harrison, DL; Schaeffer, SE | 1 |
| Davis, M; Kabra, R; Kimmons, LA; Oliphant, CS; Segars, BV | 1 |
| Ragni, MV | 1 |
| Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Bounameaux, H; Verhamme, P | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Aumann, V; Boxberger, N; Hartung, KJ; Heim, MU; Siegemund, A | 1 |
| Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
| Akbar Ali, M; Chee, YL; Handa, PK; Lee, LH; Lim, LC; Ng, HJ; Ponnudurai, K; Tan, D; Tay, JC | 1 |
| Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T | 1 |
| Almutawa, M; Ghanny, S; Goy, JK; Nahirniak, S; Ritchie, B; Schulman, S | 1 |
| Crowther, MA; Garcia, DA; Siegal, DM | 1 |
| Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB | 1 |
| Goto, S; Tomita, A | 1 |
| Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Miller, MP; Nordenholz, KE; Trujillo, TC | 1 |
| Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Acket, B; Bagheri, H; Bourrel, R; Lavezzi, O; Molinier, A; Montastruc, JL | 1 |
| Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L | 1 |
| Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Brunetti, L; Chen, C; White, J | 1 |
| Begg, EJ; Chin, PK; Doogue, MP; Patterson, DM; Wright, DF | 1 |
| Keeling, D; Wong, H | 1 |
| Antoniazzi, S; Berdaï, D; Clementi, E; Conti, V; Salvo, F | 1 |
| Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C | 1 |
| Iung, B; Vahanian, A | 1 |
| Clemens, A; Kink-Eiband, M; Schurer, J; van Ryn, J | 1 |
| Thachil, J | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Ibrahim, S; Jespersen, J; Poller, L | 2 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brieger, D | 1 |
| Cohen, AT; Imfeld, S; Rider, T | 1 |
| Dempfle, CE | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC | 1 |
| Expósito, V; Fernández-Fresnedo, G; Seras, M | 1 |
| Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD | 1 |
| Bruyère, O; Buckinx, F; Dogné, JM; Douxfils, J; Hainaut, P; Minet, V; Mullier, F; Rabenda, V; Reginster, JY | 1 |
| Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S | 1 |
| Lévy, S | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Barçın, C; Demir, M; Kabul, HK; Yalçınkaya, E | 1 |
| Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A | 1 |
| Ansell, J; Mantha, S | 2 |
| Cowell, RP | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Cohen, D | 2 |
| Charlton, B; Redberg, R | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Cohen, MR; Mattison, DR; Moore, TJ | 1 |
| Kmietowicz, Z | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Amirehsani, KA; Scott, KA | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF | 1 |
| Dickneite, G; Doerr, B; Herzog, E; Kaspereit, FJ; Krege, W; Pragst, I; van Ryn, J | 1 |
| Donovan, JL; Kanaan, AO; Rollins, BM; Silva, MA | 1 |
| Husted, SE; Thorup, SB; Vang, ML | 1 |
| Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J | 1 |
| Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT | 1 |
| Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Banfi, R; Fallani, F; Palazzi, N; Pugi, A | 1 |
| Connolly, SJ; Wallentin, L; Yusuf, S | 1 |
| Howell, G; Pluym, M | 1 |
| Lütken, SC; Løfgren, B; Madsen, HB; Povlsen, JA | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| Hvas, AM; Skjødt-Jensen, AM | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Redberg, RF | 1 |
| Baik, SH; Hernandez, I; Piñera, A; Zhang, Y | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Beyer-Westendorf, J | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Aita, A; Angeli, F; Bartolini, C; De Filippo, V; di Giacomo, L; Martone, S; Molini, G; Reboldi, G; Valecchi, F; Verdecchia, P | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 1 |
| Gierek, D; Lasek-Bal, A; Urbanek, T | 1 |
| Getta, B; Hsu, D; Motum, P; Muller, N; Rosenfeld, D; Zebeljan, D | 1 |
| Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
| Deitelzweig, SB; Jing, Y; Makenbaeva, D; Swindle, JP | 1 |
| Awad, NI; Brunetti, L; Juurlink, DN | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Beliavskaia, OO; Vavilova, TV | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Hoffman, M; Monroe, DM; Volovyk, Z | 1 |
| Peacock, WF | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Chan, NC; Coppens, M; Douketis, JD; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Schulman, S; Vanassche, T; Weitz, JI | 1 |
| Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L | 1 |
| Belikov, LN; Savchuk, OF; Sukovatykh, BS; Sukovatykh, MB | 1 |
| Blann, AD | 1 |
| Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Bultas, J; Karetová, D | 1 |
| Marcus, H; Nandi, D; Tai, D; Vakharia, NN; Vakharia, VN | 1 |
| Bernier-Jean, A; Bouchard, J; Eris, JM; Ghannoum, M; Kershaw, G; Patel, JP; Roberts, DM; Tran, H; Weatherburn, C; Williamson, D | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Bultas, J | 1 |
| Garcia, DA; Kim, B | 1 |
| Bacchus, F; Schulman, S | 1 |
| Cantillon, D; Coleman, CM; Kanj, M; Khalaf, S; Mould, S; Saliba, W; Wazni, O | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Beyer-Westendorf, J; Daschkow, K; Ebertz, F; Endig, H; Förster, K; Gelbricht, V; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Tittl, L; Weiss, N; Werth, S | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AK; Kearon, C; Kreuzer, J; Schellong, S; Schulman, S | 1 |
| Oberhofer, E | 1 |
| Steiner, T | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Greinacher, A; Selleng, K; Thiele, T | 1 |
| Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M | 1 |
| Abdollah, H; Baranchuk, A; Enriquez, A; Michael, K; Redfearn, D; Simpson, C | 1 |
| Bertran, EA; Forman, MJ; Hoffman, JL; Koerber, JM; Priziola, JL; Smythe, MA | 1 |
| Abe, J; Kato, Y; Kinosada, Y; Nagasawa, H; Nakamura, M; Nakayama, Y; Suzuki, T; Suzuki, Y; Ueda, N; Umetsu, R | 1 |
| Lane, DA; Wood, K | 1 |
| Gehrie, E; Tormey, C | 1 |
| Beyer-Westendorf, J; Breslin, T; NiAinle, F; Werth, S | 1 |
| Barty, R; Blostein, M; Carrier, M; Douketis, JD; Heddle, N; Lee, AY; Schulman, S; Shivakumar, S; Solymoss, S; Spencer, FA; Wang, G | 1 |
| Antovic, JP; Božič-Mijovski, M; Malmström, RE; Mavri, A; Pohanka, A; Rönquist-Nii, Y; Šinigoj, P; Vene, N | 1 |
| Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N | 1 |
| Dogné, JM; Douxfils, J; Mullier, F | 1 |
| Bernstein, R; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, E; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, F; Stangier, J; Steiner, T; Wang, B; Weitz, JI | 1 |
| Karbyshev, IA; Petrikov, AS; Shoikhet, YN; Vyatkin, DA; Zakharchenko, KK | 1 |
| Saliba, W | 1 |
| Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK | 1 |
| Fanola, CL | 1 |
| Mateo Arranz, J; Millón Caño, JA; Souto Andrés, JC; Vilalta Setó, N | 1 |
| Lip, GY; Proietti, M | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F | 1 |
| Bernstein, RA; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Weitz, JI | 1 |
| Chen, Q; Dai, P; Gong, G; Wang, S; Xu, Y; Zhu, Q | 1 |
| Ageno, W; Riva, N | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Berry, A; Ehrlich, C; Tsu, LV; Wald, E | 1 |
| Law, EH; Leung, TS | 1 |
| Alla, F; Billionnet, C; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç | 1 |
| Alonso-Coello, P; Brosa, M; Carles, M; Garcia-Alamino, JM; Guyatt, G; Souto, JC | 1 |
| Goette, A; Hammwöhner, M | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Connolly, SJ; Ezekowitz, MD; Fukaya, T; Hori, M; Kleine, E; Reilly, PA | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Boonyawat, K; Chai-Adisaksopha, C; Crowther, M; Hillis, C; Lim, W; Moffat, K | 1 |
| Jugrin, AV; Lamotte, M; Sunderland, T; Urbich, M; Ustyugova, A | 1 |
| Rondina, MT; Vazquez, S | 1 |
| Holzgreve, H | 1 |
| Chan, NC; Fredenburgh, JC; Jaffer, IH; Stafford, AR; Weitz, JI; Whitlock, RP | 1 |
| Kusano, K; Miyamoto, K; Nakasuka, K | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Maron, B; Rossaint, R; Spronk, HM; ten Cate, H; van Ryn, J | 1 |
| Buitrago, F; Capilla Lozano, F; Gallego Fuentes, R; Rodríguez Pérez, L | 1 |
| Schlimpert, V | 1 |
| De Francesco, M; Hösel, V; Jugrin, AV; Lamotte, M; Sunderland, T; Ustyugova, A | 1 |
| Eriksson, H; Feuring, M; Friedman, J; Goldhaber, SZ; Hantel, S; Kakkar, A; Kearon, C; Kreuzer, J; Majeed, A; Schellong, S; Schulman, S | 1 |
| Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; ten Cate, H; van Ryn, J | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; Ten Cate, H; van Ryn, J | 1 |
| Egami, Y; Hara, M; Makino, N; Mori, N; Nishino, M; Okamoto, N; Shutta, R; Tanaka, A; Tanouchi, J; Yano, M | 1 |
| Collins, J; Fraeman, K; Reynolds, MW; Schnee, J; Schwartzman, E; Siu, K; Villines, TC | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD; Zint, K | 1 |
| Ackery, A; Sholzberg, M; Wood, B | 1 |
| Riess, H | 1 |
| Cei, M; Dentali, F; Fiorini, M; Mumoli, N; Pennati, P; Testa, S | 1 |
| McCarthy, M | 1 |
| Gorbunova, EV; Mamchur, SE; Romanova, MP; Sherbinina, DA | 1 |
| Avgil Tsadok, M; Humphries, KH; Jackevicius, CA; Pilote, L; Rahme, E | 1 |
| Barty, R; Blostein, M; Chan, N; Douketis, JD; Eikelboom, JW; Moffat, KA; Schulman, S; Spencer, FA; Syed, S; Wang, G | 1 |
| Bänsch, D; Linhart, M; Nickenig, G; Schrickel, JW; Thomas, D | 1 |
| Bianchi, V; Calabrò, P; Cavallaro, C; D'Onofrio, A; De Vivo, S; Nigro, G; Russo, V; Santangelo, L; Sarubbi, B; Vecchione, F | 1 |
| Bouget, J; Oger, E | 1 |
| Burness, CB | 1 |
| Gnjidic, D; Hanger, HC; Hilmer, SN; Jamieson, HA; Kaluarachchi, C; Nishtala, PS | 1 |
| Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Cuker, A; Siegal, D | 1 |
| Roca, B; Roca, M | 1 |
| Bruno, A; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Tate, N; Trocio, J | 1 |
| Bajalan, M; Biggs, TC; Jayaram, S; Mainwaring, J; Salib, R | 1 |
| Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H | 1 |
| Bernstein, RA; Eikelboom, J; Huisman, MV; Hylek, E; Kam, CW; Kamphuisen, P; Levy, JH; Pollack, CV; Reilly, PA; Steiner, T; Weitz, JI | 1 |
| Andersson, U; Aulin, J; Connolly, SJ; Ezekowitz, MD; Hijazi, Z; Huber, K; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L | 1 |
| Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Aonuma, K; Goya, M; Hirao, K; Nogami, A | 1 |
| Hussein, A; Saliba, W; Wazni, OM | 1 |
| Eikelboom, JW; Quinlan, DJ; van Ryn, J; Weitz, JI | 1 |
| Agewall, S; Atar, D; Drexel, H; Husted, SE; Kaski, JC; Kjeldsen, K; Koller, L; Lewis, BS; Lip, GYH; Morais, J; Niessner, A; Storey, RF; Tamargo, J; Torp-Pedersen, C; Verheugt, FWA; Wassmann, S | 1 |
| Dechering, DG; Eckardt, L; Foraita, P; Güner, F; Kochhäuser, S; Lange, PS; Leitz, P; Mönnig, G; Pott, C; Wasmer, K; Zellerhoff, S | 1 |
| Didier, R; Escarcega, RO; Kiramijyan, S; Koifman, E; Lipinski, MJ; Torguson, R; Waksman, R | 1 |
| Rostagno, C | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Aguilar-Salvatierra, A; Calvo-Guirado, JL; de Carlos, F; Delgado-Ruiz, RA; Fernández-Cejas, E; Gómez-Moreno, G | 1 |
| Amylidi, AL; Exadaktylos, AK; Lehmann, B; Ricklin, ME; Sauter, TC | 1 |
| Angoulvant, D; Babuty, D; Bejan-Angoulvant, T; Darwiche, W; Dievart, F; Fauchier, L | 1 |
| Bartels, GL; Geluk, CA; Korenstra, J; Piersma-Wichers, M; Posma, JL; Rienstra, M; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wijtvliet, EP | 1 |
| Lu, L; Rong, G; Wang, H; Zhang, J; Zhou, Y | 1 |
| Dollard, E; Eaves, S; Kuyumjian, Y; Miyares, MA | 1 |
| Doolin, M; Isaacs, AN; Morse, C; Nisly, SA; Shiltz, E | 1 |
| Chin, PK; Fox, A; Marais, M; Tiong, J | 1 |
| Brueckmann, M; Connolly, S; Eikelboom, JW; Feuring, M; Hwang, HG; Majeed, A; Noack, H; Schulman, S; Wallentin, L; Yusuf, S | 1 |
| Dee, S; Jayathissa, S; Thorne, K | 1 |
| Brueckmann, M; Connolly, SJ; Douketis, JD; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Healey, JS; Oldgren, J; Reilly, P; Spyropoulos, AC; Wallentin, L; Yusuf, S | 1 |
| Ayala-Paredes, F; Birnie, DH; Coutu, B; Coyle, D; Eikelboom, J; Essebag, V; Healey, JS; Kalfon, E; Nery, P; Philippon, F; Sandhu, RK; Sapp, J; Verma, A; Wells, G | 1 |
| Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D | 1 |
| Kaufner, L; Rosenthal, C; Sander, M; von Heymann, C | 1 |
| Gauthier-Lewis, ML; Riley, TR; Riley, TT; Sanchez, CK | 1 |
| Grottke, O; Petersen, PF | 1 |
| Einecke, D | 2 |
| Boda, Z | 1 |
| Chang, PM; Chang, SL; Chang, YT; Chao, TF; Chen, SA; Chern, CM; Chiou, CW; Chung, CP; Hsu, LC; Hsu, WH; Hu, YF; Liao, JN; Lin, YJ; Lo, LW; Lu, TM; Sung, SH; Wang, KL; Wu, CH | 1 |
| Garg, AX; Gomes, T; Harel, Z; Juurlink, DN; Mamdani, M; Wald, R; Yao, Z | 1 |
| Cave, G; Chauhan, A; Damitz, R; Harvey, M; Hunter, N; Wu, Z | 1 |
| Loffredo, L; Perri, L; Violi, F | 1 |
| Majeed, A; Schulman, S; Shrum, J | 1 |
| Harenberg, J | 1 |
| Ghosh, RK; Gupta, A; Kavtaradze, A; Tummala, R | 1 |
| Marra, A; Perrone, A; Servillo, G; Vargas, M | 1 |
| Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Dager, W; Hellwig, T | 1 |
| Fanikos, J; Smythe, MA; Trujillo, T | 1 |
| Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
| Greinacher, A; Vanassche, T; Verhamme, P | 1 |
| Aronow, WS; Chatterjee, S; Kundu, A; Owan, T; Ryan, JJ; Sardar, P | 1 |
| Owusu, K; Reardon, DP | 1 |
| Coscioni, E; Izzo, R; Losi, MA; Rozza, F; Stabile, E; Trimarco, B | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Brueckmann, M; Clemens, A; Feuring, M; Frostick, SP; Gullberg, J; Kleine, E; Rosencher, N; Samama, CM | 1 |
| Hussain, SS; Mukherjee, D; Tyroch, AH | 1 |
| Eddings, W; Franklin, JM; Gagne, JJ; Glynn, RJ; Schneeweiss, S; Wang, SV | 1 |
| Bjerregaard Larsen, T; Gorst-Rasmussen, A; Lip, GY | 1 |
| Bair, TL; Bunch, TJ; Crandall, BG; Cutler, MJ; Day, JD; Jacobs, V; Mallender, C; May, HT; Osborn, JS; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Hart, C; Schmid, S | 1 |
| Boey, JP; Gallus, A | 1 |
| Cappato, R; De Caterina, R; Ezekowitz, MD; Giugliano, RP; Patel, MR; Piccini, JP; Renda, G; Ricci, F; Zimarino, M | 1 |
| Sié, P | 1 |
| Godier, A; Martin, AC; Rosencher, N; Susen, S | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
| Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW | 1 |
| Kaboli, PJ; Kalil, RS; Liu, X; Vaughan-Sarrazin, M | 1 |
| Sellke, FW; Sodha, NR | 1 |
| Comer, AC; Dezman, ZD; Hess, JR; Hirshon, JM; Narayan, M; Smith, GS | 1 |
| Ako, J; Fujiishi, T; Fukaya, H; Horiguchi, A; Igarashi, T; Ishizue, N; Kishihara, J; Murakami, M; Nakamura, H; Nishinarita, R; Niwano, S; Oikawa, J; Satoh, A; Yoshizawa, T | 1 |
| Syed, YY | 1 |
| Higashiya, S; Hina, K; Kamikawa, S; Kawamura, H; Komtasubara, I; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Ditch, K; Doyno, C; Fong, JJ; Medeiros, K; Yogaratnam, D | 1 |
| Agnelli, G; Becattini, C; Cianella, F; Conti, S; Filippucci, E; Giustozzi, M; Marchesini, E; Pierpaoli, L; Vedovati, MC; Verdecchia, P; Verso, M | 1 |
| Abraham, NS; Bellolio, MF; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Chien, KL; Hu, MM; Lin, SY; Lin, ZF; Su, CL; Wang, J; Wu, FL | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Beshir, SA; Chee, KH; Lo, YL | 1 |
| Darocha, T; Drwiła, R; Filip, G; Grudzień, G; Kapelak, B; Mazur, P | 1 |
| Carmo, J; Ferreira, J; Mendes, M; Moscoso Costa, F | 1 |
| Clemens, A; Hösel, V; Klok, FA; Konstantinides, SV; Lankeit, M; Schulman, S; Tilke, C; Yollo, WD | 1 |
| Ageno, W; Büller, HR; Camm, AJ; Falanga, A; Hacke, W; Hendriks, J; Lobban, T; Merino, J; Milojevic, IS; Moya, F; Randall, G; Tsioufis, K; van der Worp, HB; Verhamme, P | 1 |
| Hamilton, M; Horblyuk, R; Kamble, S; Keshishian, A; Lip, GY; Mardekian, J; Pan, X | 1 |
| Berger, K; Lesch, CA; Sin, JH | 1 |
| Schwartz, JB | 1 |
| Bruno, A; Kamble, S; Kawabata, H; Lip, GY; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Imazu, T; Kimura, R; Maeda, Y; Matsuda, S; Matsumoto, A; Murakami, T; Nakamura, M | 1 |
| Bhatt, DL; Blatchford, J; Brueckmann, M; Cannon, CP; Ellis, SG; Ferreiros Ripoll, E; Gropper, S; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GY; Manassie, J; Massaro, JM; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Milling, TJ; Spyropoulos, AC | 1 |
| Peacock, WF; Villines, TC | 2 |
| Fanikos, J; Huisman, MV | 2 |
| Glund, S; Grottke, O; Reilly, PA; Stangier, J; van Ryn, J | 1 |
| Bickley, AR; Wallace, C | 1 |
| Berliner, N; Connell, NT; Connors, JM; Dew, RB; Marino, KK; Santiago, RA; Tucker, JK | 1 |
| Eikelboom, J; Merli, G | 2 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Steed, MB; Swanson, MT | 1 |
| Hernandez, I; Zhang, Y | 1 |
| Henry, BL; Kumar, R; Rahman, AM | 1 |
| Brenner, T; Hofer, S; Philipsenburg, C; Weigand, MA | 1 |
| Falck, P; Fride Tvete, I; Ghanima, W; Halvorsen, S; Hoxmark, C; Jonasson, C; Solli, O | 1 |
| Torjesen, I | 1 |
| Bajorek, BV; Pandya, E | 1 |
| Ferreira, JA; Miller, L; Tucker, C | 1 |
| Dyrkorn, R; Lundgaard, H; Molden, E; Spigset, O; Stokes, CL | 1 |
| Barrios, V; Masjuan, J | 1 |
| Drici, MD; Ichai, C; Quintard, H; Ruetsch, C; Samama, CM; Viard, D | 1 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| Assar, MD; Ball, T; Cox, KM; McCullough, PA | 1 |
| Keskar, V; Sood, MM | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Altiparmak, IH; Besli, F | 1 |
| Braemswig, TB; Eschenfelder, CC; Nolte, CH | 1 |
| Ageno, W; Casella, IB; Desch, M; Goldhaber, SZ; Han, CK; Kimura, K; Raskob, GE; Schellong, S; Schulman, S; Singer, DE; Tang, W | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Douglas, JS; Gauthier-Lewis, ML; Riley, TR; Sanchez, CK | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD | 1 |
| Brooks, MM; Chin, PK; Hernandez, I; Saba, S; Zhang, Y | 1 |
| Crowther, MA; Shih, AW | 1 |
| Kawada, T | 1 |
| Bernstein, R; Dubiel, R; Gruenenfelder, F; Huisman, MV; Kam, CW; Kleine, E; Levy, JH; Pollack, CV; Reilly, P; Sellke, FW; Steiner, T; Ustyugova, A; Weitz, JI | 1 |
| Heard, LK; Maggio, KL; Shanahan, C | 1 |
| Balla, S; Flaker, G; Koerber, S | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Góralczyk, T; Malec, K; Undas, A | 1 |
| Antoniak, S; Bastarache, JA; Beck, MA; Gondouin, B; Mackman, N; Mickelson, J; Monroe, DM; Neidich, SD; Subramaniam, S; Tatsumi, K | 1 |
| Finks, SW; Rogers, KC | 1 |
| Bhurtu, A; Bundhun, PK; Huang, WQ; Pursun, M; Soogund, MZ; Teeluck, AR | 1 |
| Weißbach, L; Zotz, RB | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Agnelli, G; Aita, A; Becattini, C; Conti, S; Giustozzi, M; Molini, G; Pierpaoli, L; Valecchi, F; Vedovati, MC; Verdecchia, P | 1 |
| Broscaru, L; Gulba, DC | 1 |
| Chung, MK; Cigarroa, JE; Collins, SP; Diaz-Sandoval, LJ; Diercks, D; Jung, HS; Piccini, JP; Raval, AN; Washam, JB; Welch, BG; Zazulia, AR | 1 |
| Baryah, HS; Chandan, JS; Thomas, T | 1 |
| Cong, J; Fromm, C; Ganetsky, M; Milling, TJ; Pallin, DJ; Singer, AJ | 1 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Lip, GY; Potpara, TS | 1 |
| Weitz, JI | 1 |
| Bocksrucker, C; Drwiła, R; Dulíček, P; Hauer, T; Mutzenbach, J; Schlimp, CJ; Špinler, D; Vosko, MR; Wolf, T; Zugwitz, D | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AJ; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Connolly, SJ; Coppens, M; Eikelboom, JW; Ezekowitz, M; Lauw, MN; Nakamya, J; Oldgren, J; Wallentin, L; Wang, J; Yusuf, S | 1 |
| Dowlatshahi, D; Frymire, E; Giulivi, A; Gomes, T; Holbrook, AM; Johnson, AP; Khuu, W; Mamdani, M; Schulman, S; Shepherd, LE; Simpson, CS; Wells, PS; Xu, Y | 1 |
| Carrier, M; Gross, PL; Hwang, HG; Majeed, A; Nahirniak, S; Ritchie, B; Schulman, S; Zondag, M | 1 |
| Glund, S; Haazen, W; Harada, A; Ikushima, I; Imazu, S; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, PA; Stangier, J | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Franca, LR; Haertter, S; Huang, F | 1 |
| Antoniou, T; Juurlink, D; Mamdani, M | 1 |
| Antoniou, T; Gomes, T; Hollands, S; Juurlink, DN; Macdonald, EM; Mamdani, MM; Tadrous, M; Yao, Z | 1 |
| Bliden, KP; Chaudhary, R; Cohen, E; Doubleday, M; Gurbel, PA; Lopez-Espina, CG; Mathew, B; Mohammed, N; Muresan, AA; Raviv, G; Tantry, US; Zaman, F | 1 |
| Desborough, MJ; Shapiro, S; Zhang, XY | 1 |
| Bundhun, PK; Chaudhary, N; Yuan, J | 1 |
| Plosker, GL; Sanford, M | 1 |
| Eikelboom, JE; Weitz, JI | 1 |
| Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE | 1 |
| Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE | 1 |
| Lassen, MR; Laux, V | 1 |
| Arnaout, L; Bellamy, L; Rosencher, N | 1 |
| Crain, EJ; Watson, CA; Wong, PC; Xin, B | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Hankey, GJ | 1 |
| Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE | 1 |
| Gattellari, M; Worthington, JM | 1 |
| Mannucci, PM; Moia, M | 1 |
| Prandoni, P; Taher, A | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM | 1 |
| Azuma, J; Maegdefessel, L; Spin, JM; Tsao, PS | 1 |
| Brant, R; Hull, RD; Liang, J | 1 |
| Barrios, V; Escobar, C; Jimenez, D | 1 |
| Alings, M; Connolly, SJ; Dans, A; Eikelboom, J; Ezekowitz, MD; Flather, M; Franzosi, MG; Oldgren, J; Pais, P; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Lane, DA; Lip, GY | 2 |
| Ageno, W; Rancan, E; Romualdi, E; Siragusa, S | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Clemens, A; Lip, GY; Noack, H; Plumb, JM; Roskell, NS | 1 |
| Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Connolly, SJ; Ezekowitz, MD; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Oliver, M | 1 |
| Kwok, CS; Loke, YK | 1 |
| Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Hantel, S; Hermansson, K; Huo, MH; Kurth, AA; Schnee, JM | 1 |
| Samama, CM | 1 |
| Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM | 1 |
| Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Beasley, BN; Temple, R; Unger, EF | 1 |
| Alonso de Leciñana, M; Aparicio, M; Buisan, J; García-Caldentey, J; Guillán, M; Masjuan, J; Matute, MC | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Gage, BF; Shah, SV | 1 |
| Fareed, J; Hull, R; Welzel, D | 1 |
| Gawaz, M; Geisler, T | 1 |
| Lee, TH | 1 |
| Kazmi, RS; Lwaleed, BA | 1 |
| Qureshi, AI; Siddiqui, FM; Watanabe, M | 1 |
| Gage, L | 1 |
| Jacobs, JM; Stessman, J | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD | 1 |
| Pernod, G | 1 |
| Hunchuck, JE; Lake, JD | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
| Augoustides, JG | 1 |
| Heidinger, K; Kemkes-Matthes, B | 1 |
| Jolobe, OM | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Beyth, RJ; Landefeld, CS | 1 |
| Cotton, BA; Holcomb, JB; McCarthy, JJ | 1 |
| Panchenko, EP | 1 |
| Albaladejo, P; Rosencher, N | 1 |
| Boniface, K; Moore, CH; Scott, J; Snashall, J | 1 |
| Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR | 1 |
| Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ | 1 |
| Brueckmann, M; Clemens, A; Diener, HC; Huisman, MV; Lip, GY; van Ryn, J | 1 |
| Bell, S; Dawes, M; Nand, J; Spriggs, D; Young, L | 1 |
| Comin, J; Kallmes, DF | 1 |
| Soff, GA | 1 |
| Harper, P; Merriman, E; Young, L | 1 |
| Abdelhafiz, AH; Ali, A; Bailey, C | 1 |
| Cano, EL; Miyares, MA | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Robert, S | 1 |
| Baker, RI; Harper, P; McLintock, C | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Ilmakunnas, M; Lassila, R; Louhimo, J | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Lewalter, T | 1 |
| Little, JW | 1 |
| Béné, J; Coupe, P; Deheul, S; Gautier, S; Rannou, M; Saïd, W | 1 |
| Gil Núñez, A | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Gállego, J; Gil Alzueta, MC | 1 |
| Garcia, DA; Granger, CB | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Bhatt, DL; Kar, S | 1 |
| Radecki, RP | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Bilen, O; Teruya, J | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Huang, C; Shin, J; Siu, M; Vu, L; Wong, S | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A | 1 |
| Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Cannon, CP; Kohli, P | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Basciano, P; Chen, BC; Garlich, FM; Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW; Viny, AD | 1 |
| Adachi, T; Isoda, K; Kimura, T; Yokoi, K | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Brunner, K; Ehrenschwender, M; Koessler, J; Steigerwald, U | 1 |
| Esmon, CT | 1 |
| Le Heuzey, JY | 1 |
| Tripodi, A | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Aalbers, J; Hardy, G | 1 |
| Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE | 1 |
| Loor, MM; Moorman, ML; Obeng-Gyasi, S; Samotowka, MA | 1 |
| Pieracci, FM | 1 |
| Haschke, M | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Harinstein, LM; Morgan, JW; Russo, N | 1 |
| Barrios, V; Escobar, C | 1 |
| Crijns, HJ; Lane, DA; Lip, GY; Nieuwlaat, R; Pisters, R | 1 |
| Crowther, MA; Siegal, DM | 1 |
| Ortel, TL | 1 |
| Pawlikowska, Z; Szponar, J | 1 |
| Brueckmann, M; Connolly, SJ; Dans, AL; Eikelboom, JW; Ezekowitz, M; Nakamya, J; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Deitelzweig, SB | 1 |
| Best, M; Jones, QC; Palmer, K; Wathen, CG | 1 |
| Chance, EA; Huang, GS | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Livio, F | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Breik, O; Devitt, P; Tadros, R | 1 |
| Ahnfelt, L; Dahl, OE; Eriksson, BI; Hermansson, K; Kälebo, P; Kohlbrenner, V; Nehmiz, G; Stangier, J | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Büller, HR; Christiansen, AV; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kälebo, P; Kurth, AA; Rosencher, N; Schnee, J; van Dijk, CN | 1 |
| Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN | 1 |
324 review(s) available for dabigatran and Bleeding
| Article | Year |
|---|---|
Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis.
Topics: Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis | 2021 |
Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans | 2022 |
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Ticagrelor; Warfarin | 2022 |
Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review.
Topics: Anticoagulants; Blood Coagulation Disorders; Dabigatran; Emergencies; Hemorrhage; Humans; Vitamin K | 2022 |
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2022 |
Drug Interactions Affecting Oral Anticoagulant Use.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Hemorrhage; Humans; Pyridones; Rivaroxaban; Warfarin | 2022 |
The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Rivaroxaban; Stroke; Vitamin K | 2022 |
Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Child; Dabigatran; Hemorrhage; Humans; Venous Thromboembolism | 2022 |
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Thrombosis; Venous Thromboembolism; Vitamin K | 2022 |
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Mass Index; Body Weight; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2022 |
Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Child; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2023 |
Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Network Meta-Analysis; Rivaroxaban; Venous Thromboembolism; Warfarin | 2022 |
Use of tramadol and the risk of bleeding complications in patients on oral anticoagulants: a systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Tramadol; Vitamin K | 2022 |
Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article.
Topics: Administration, Oral; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Heparin; Humans; Thromboembolism | 2023 |
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2022 |
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
The Risk of Postpolypectomy Bleeding in Patients Receiving Direct Oral Anticoagulants compared to Warfarin or Nonanticoagulation: A Systematic Review with Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Retrospective Studies; Warfarin | 2022 |
DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Hemostasis; Hemostatics; Humans; Thrombin | 2023 |
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Incidence; Japan; Product Surveillance, Postmarketing; Pyridones; Rivaroxaban; Stroke | 2023 |
When and How to Use Reversal Agents for Direct Oral Anticoagulants?
Topics: Administration, Oral; Anticoagulants; Antidotes; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins | 2023 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasm Recurrence, Local; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis | 2023 |
Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Relevance; Dabigatran; Hemorrhage; Humans; Prospective Studies; Recombinant Proteins; Retrospective Studies | 2023 |
Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Hemorrhage; Hemostatics; Humans; Thromboembolism | 2023 |
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Direct oral anticoagulants and their antagonists in perioperative practice.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2023 |
Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2023 |
Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Tract; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2023 |
Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice.
Topics: Administration, Oral; Anticoagulants; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Heparin; Humans | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke | 2023 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2020 |
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Care Bundles; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2020 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2020 |
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Vitamin K | 2020 |
Periprocedural Management of Oral Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Surgical Procedures, Operative; Warfarin | 2020 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Liver Diseases; Pyrazoles; Pyridones; Stroke | 2021 |
Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome | 2020 |
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thrombophilia; Venous Thromboembolism | 2021 |
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
Direct oral anticoagulants: evidence and unresolved issues.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Italy; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2021 |
Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Venous Thrombosis | 2021 |
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; Venous Thromboembolism; Warfarin | 2021 |
Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2022 |
Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Risk Factors; Thromboembolism | 2021 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversing the anticoagulation effects of dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Watchful Waiting | 2017 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
Bleeding Complications and Management on anticoagulant therapy.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Vitamin K | 2017 |
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Geriatrics; Hemorrhage; Humans; Metabolic Clearance Rate; Renal Insufficiency, Chronic; Warfarin | 2017 |
[Management of hemorrhage in patients treated with direct oral anticoagulants].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Humans; Prothrombin; Thromboembolism | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2017 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Anticoagulant Reversal and Anesthetic Considerations.
Topics: Anesthetics; Anticoagulants; Antithrombins; Blood Coagulation Factors; Coagulants; Dabigatran; Factor VIIa; Factor Xa Inhibitors; Hemorrhage; Humans; Protamines; Vitamin K | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Clinical Trials as Topic; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Markov Chains; Middle Aged; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk; Thiazoles; Warfarin | 2017 |
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Myocardial Infarction; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Factor Xa; Hemorrhage; Humans; Recombinant Proteins; Stroke; Thrombolytic Therapy; Vitamin K | 2017 |
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Practice Guidelines as Topic; Stroke; Tissue Plasminogen Activator | 2017 |
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male | 2017 |
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis; Vitamin K | 2017 |
Idarucizumab: What Should We Know?
Topics: Animals; Antibodies, Monoclonal, Humanized; Antithrombins; Clinical Trials as Topic; Dabigatran; Drug Evaluation, Preclinical; Hemorrhage; Humans | 2018 |
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Benzamides; Blood Loss, Surgical; Dabigatran; Deprescriptions; Elective Surgical Procedures; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
An update on the bleeding risks associated with DOACs.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2017 |
Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2018 |
[Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2017 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
Novel oral anticoagulants in the preoperative period: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Preoperative Period; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2018 |
[Antidote treatment during use of direct anticoagulants].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles | 2018 |
What is the Role of Reversal Agents in the Management of Emergency Department Patients with Dabigatran-Associated Hemorrhage?
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Anticoagulants; Cohort Studies; Dabigatran; Emergency Service, Hospital; Hemorrhage; Humans; Male; Middle Aged; United States; United States Food and Drug Administration | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
How I manage patients with anticoagulation-associated bleeding or urgent surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2018 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2018 |
[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tests; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Premedication; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism | 2018 |
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Rivaroxaban; Treatment Outcome; Vitamin K | 2018 |
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).
Topics: Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Neoplasms; Patient Discharge; Patient Selection; Pregnancy; Pregnancy Complications, Cardiovascular; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Substance Abuse, Intravenous; Thiazoles | 2018 |
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K | 2018 |
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Cerebral Infarction; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Postoperative Hemorrhage; Risk Factors; Rivaroxaban; Severity of Illness Index; Thromboembolism; Warfarin | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Insufficiency; Rivaroxaban | 2019 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; Warfarin | 2019 |
Strategies of neutralization of the direct oral anticoagulants effect: review of the literature.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Rivaroxaban | 2019 |
idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
Topics: Administration, Intravenous; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Dabigatran; Hemorrhage; Humans | 2016 |
Atrial Fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2019 |
Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2020 |
Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Coagulants; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Treatment Outcome | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Emergency Medical Services; Factor X; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Inpatients; Medical Staff, Hospital; Recombinant Proteins | 2019 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Disease Management; Drug Overdose; Emergency Service, Hospital; Hemorrhage; Humans; Postoperative Hemorrhage | 2014 |
Dabigatran: life-threatening bleeding.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Risk Assessment; Risk Factors; Thrombosis; Treatment Outcome | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Managing blunt trauma in patients receiving dabigatran etexilate: case study and review of the literature.
Topics: Accidental Falls; Aged; Benzimidazoles; Dabigatran; Dementia; Female; Hemorrhage; Humans; Pneumothorax; Pyridines; Rib Fractures; Spleen; Thoracostomy; Vitamin K; Wounds, Nonpenetrating | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Dyspepsia; Electric Countershock; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Stents; Stroke; Treatment Outcome | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
Dabigatran and kidney disease: a bad combination.
Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation Tests; Charcoal; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Kidney Diseases; Plasma; Renal Replacement Therapy | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyridines; Risk Factors; Stroke; Treatment Outcome | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Odds Ratio; Pyridines; Risk Factors; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Chi-Square Distribution; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Odds Ratio; Pyridines; Risk Factors; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Morpholines; Perioperative Care; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thrombin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2013 |
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrhage; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thromboembolism | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Hemorrhage; Humans; Risk Factors; Stroke | 2014 |
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
Topics: Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Thrombin Time; Thromboembolism | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Stroke; Venous Thromboembolism | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2014 |
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke | 2015 |
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Venous Thromboembolism | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thrombosis | 2015 |
Direct oral anticoagulants: integration into clinical practice.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Warfarin | 2014 |
[Monitoring options and reversal agents for oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2014 |
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Hemorrhage; Humans; Pyrazoles; Pyridones; Risk Factors | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Enhanced elimination of dabigatran through extracorporeal methods.
Topics: Antithrombins; Biological Availability; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Overdose; Emergency Medical Services; Evidence-Based Medicine; Hemodiafiltration; Hemorrhage; Humans; Renal Elimination; Tissue Distribution; Up-Regulation | 2015 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
New oral anti-coagulants: Implications for neurosurgery.
Topics: Animals; Anticoagulants; Dabigatran; Hemorrhage; Humans; Neurosurgery; Pyrazoles; Pyridones; Warfarin | 2015 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Reversal of anticoagulants: an overview of current developments.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzamides; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostatics; Heparin; Humans; Infusions, Parenteral; Intracranial Hemorrhages; Polysaccharides; Protamines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombosis; Vitamin K | 2015 |
Dabigatran for the prevention and treatment of thromboembolic disorders.
Topics: Animals; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Intracranial Hemorrhages; Stroke; Thromboembolism | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thromboembolism; Vitamin K | 2015 |
Dose tailoring of dabigatran etexilate: obvious or excessive?
Topics: Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Genetic Variation; Hemorrhage; Humans; Thrombosis | 2015 |
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Comorbidity; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Risk Factors; Sex Factors; Stroke; Vitamin K | 2015 |
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Venous Thromboembolism; Vitamin K | 2015 |
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Topics: Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis | 2015 |
The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?
Topics: Animals; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Topics: Aged; Aged, 80 and over; Antithrombins; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Dialysis; Risk Factors; Treatment Outcome | 2015 |
[Treatment of bleeding complications due to oral anticoagulant drugs].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K | 2015 |
Idarucizumab: First Global Approval.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation; Dabigatran; Drug Approval; Hemorrhage; Humans | 2015 |
Idarucizumab (Praxbind)--an antidote for dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
The new oral anticoagulants: Reasonable alternatives to warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis | 2015 |
A guide to new anticoagulant medications for ENT surgeons.
Topics: Administration, Oral; Adult; Anticoagulants; Clinical Competence; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Otolaryngology; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Surveys and Questionnaires; United Kingdom | 2015 |
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K | 2016 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Idarucizumab: The Antidote for Reversal of Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Trials, Phase I as Topic; Dabigatran; Hemorrhage; Humans; Protein Structure, Tertiary | 2015 |
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Defibrillators, Implantable; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Warfarin | 2016 |
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Polysaccharides; Rivaroxaban; Venous Thromboembolism | 2016 |
Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Vitamin K | 2016 |
Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Hemorrhage; Humans | 2015 |
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; United Kingdom; Venous Thromboembolism | 2016 |
Management of direct oral anticoagulants-associated bleeding in the trauma patient.
Topics: Administration, Oral; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Clinical Protocols; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; Wounds and Injuries | 2016 |
[Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Severity of Illness Index; Surgical Procedures, Operative; Thiazoles | 2016 |
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Clinical Trials as Topic; Dabigatran; Factor Xa; Hemorrhage; Humans; Recombinant Proteins | 2016 |
Bleeding management in patients with new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles | 2016 |
Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants.
Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans | 2016 |
Reversal agents for use with direct and indirect anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins | 2016 |
Reversal of dabigatran by idarucizumab: when and how?
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Disease Management; Drug Discovery; Drug Evaluation, Preclinical; Hemorrhage; Humans; Venous Thromboembolism | 2016 |
Minimizing the Risk of Bleeding with NOACs in the Elderly.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Precision Medicine; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Arginine; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Models, Molecular; Piperazines; Recombinant Proteins | 2017 |
[Coagulation disorders in the intensive care unit - what is new?].
Topics: Anticoagulants; Dabigatran; Hemophilia A; Hemorrhage; Heparin; Humans; Intensive Care Units; Rivaroxaban; Thrombocytopenia; Thrombosis; Warfarin | 2016 |
Drug Treatment of Venous Thromboembolism in the Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2016 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Blood Loss, Surgical; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Postoperative Hemorrhage; Risk Factors; Treatment Outcome | 2016 |
[Direct oral anticoagulant associated bleeding].
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Charcoal; Dabigatran; Hemorrhage; Humans; Prothrombin; Renal Dialysis; Stroke; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans | 2016 |
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Treatment Outcome | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Observational Studies as Topic; Stroke; Vitamin K | 2016 |
Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Chromatography, High Pressure Liquid; Dabigatran; Hemorrhage; Humans; Partial Thromboplastin Time; Prothrombin Time; Tandem Mass Spectrometry; Thrombin Time; Whole Blood Coagulation Time | 2016 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban | 2016 |
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Trials, Phase I as Topic; Dabigatran; Hemorrhage; Humans; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hemostasis, Surgical; Humans; Oral Surgical Procedures; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
A Review of the Clinical Subgroup Analyses From the RE-LY Trial.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
Evidence supporting idarucizumab for the reversal of dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Dabigatran; Emergencies; Hemorrhage; Humans; Thrombin Time; Whole Blood Coagulation Time | 2016 |
Bleeding with direct oral anticoagulants vs warfarin: clinical experience.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2016 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Safety of direct oral anticoagulants: insights from postmarketing studies.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban | 2016 |
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles | 2017 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
Role of agents for reversing the effects of target-specific oral anticoagulants.
Topics: Administration, Oral; Antithrombins; Dabigatran; Drug Evaluation; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Reversal of direct oral anticoagulants: a practical approach.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Hemorrhage; Humans; Partial Thromboplastin Time; Prothrombin Time; Recombinant Proteins; Rivaroxaban | 2016 |
Management of bleeding in patients receiving non-vitamin K antagonists.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Treatment Outcome; Warfarin | 2017 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Global Health; Hemorrhage; Humans; Incidence; Rivaroxaban; Secondary Prevention; Stroke | 2017 |
Drug interaction: dabigatran (Pradaxa) and statins.
Topics: Animals; Antithrombins; Dabigatran; Drug Interactions; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.
Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; United States; Venous Thromboembolism | 2017 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Reversal of direct oral anticoagulants.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Coagulants; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Partial Thromboplastin Time; Piperazines; Prothrombin Time; Recombinant Proteins; Thrombin Time | 2017 |
Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Global Health; Hemorrhage; Humans; Incidence; Stroke; Survival Rate | 2017 |
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism | 2009 |
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2009 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2010 |
New options with dabigatran etexilate in anticoagulant therapy.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Blood Coagulation; Cardiovascular Diseases; Dabigatran; Drug Administration Schedule; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Pyridines; Thrombin; Treatment Outcome | 2010 |
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Risk Assessment; Thrombin; Thromboembolism; Treatment Outcome | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2010 |
Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Prodrugs; Pyridines; Thromboembolism | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Partial Thromboplastin Time; Renal Dialysis | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Evidence-Based Medicine; Hemorrhage; Humans; Italy; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Fondaparinux; Heart Valve Prosthesis Implantation; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
[New anticoagulants. Characteristics, monitoring and management of bleeding].
Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2011 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemodynamics; Hemorrhage; Humans; Risk Factors; Stroke; Therapeutic Equivalency; Treatment Outcome; Ventricular Dysfunction, Left; Warfarin | 2011 |
A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Orthopedic Procedures; Pyridines; Risk Factors; Venous Thromboembolism; Venous Thrombosis | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Liver; Myocardial Infarction; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
[Dabigatran and emergency operation on a peritonitis patient].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dialysis; Emergency Treatment; Factor VIIa; Hemorrhage; Humans; Practice Guidelines as Topic | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fibrinolytic Agents; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Intracranial Embolism; Multicenter Studies as Topic; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Single-Blind Method; Thrombophilia; Vitamin K | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
[Dabigatran: a new therapeutic alternative in the prevention of stroke].
Topics: Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Double-Blind Method; Drug Interactions; Dyspepsia; Follow-Up Studies; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Tissue Plasminogen Activator | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Complications of anticoagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination; Drug Monitoring; Food-Drug Interactions; Hemorrhage; Heparin; Humans; Hypersensitivity; Injections, Subcutaneous; Necrosis; Osteoporosis; Skin Diseases; Subcutaneous Tissue; Thrombocytopenia; Warfarin | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes | 2012 |
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Drug Monitoring; Echocardiography, Transesophageal; Electric Countershock; Female; Heart Atria; Heart Rate; Hemorrhage; Humans; Male; Middle Aged; Pharmacovigilance; Risk Adjustment; Thrombosis; Treatment Outcome | 2012 |
Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Wounds and Injuries | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Treatment of dabigatran-associated bleeding: case report and review of the literature.
Topics: Aged, 80 and over; Algorithms; Antithrombins; Benzimidazoles; Dabigatran; Factor VIIa; Factor VIII; Fibrinogen; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Plasma; Pyridines; Renal Dialysis; Treatment Outcome | 2013 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Evidence-Based Medicine; Hemorrhage; Humans; Risk Factors; Stroke | 2012 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydrochloride; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Fibrinolytic Agents; Fumarates; Hemorrhage; Humans; Pharmacovigilance; Propylamines | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Thrombin inhibitors: surgical considerations and pharmacology.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Surgical Procedures, Operative | 2013 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
79 trial(s) available for dabigatran and Bleeding
| Article | Year |
|---|---|
Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.
Topics: Accidental Falls; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Retrospective Studies; Stroke; Warfarin | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Stroke; Treatment Outcome; United States; Warfarin | 2023 |
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intracranial Thrombosis; Male; Middle Aged; Prospective Studies; Single-Blind Method; Treatment Outcome; Venous Thrombosis; Warfarin | 2019 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists.
Topics: Aged; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Reperfusion; Rivaroxaban; Stroke; Thrombectomy; Treatment Outcome; Vitamin K | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Stroke; Follow-Up Studies; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrence; Treatment Outcome | 2021 |
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2021 |
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Time Factors; Warfarin | 2021 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Postoperative Complications; Stroke; Warfarin | 2017 |
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Defibrillators, Implantable; Drug Administration Schedule; Drug Substitution; Female; Hematoma; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pacemaker, Artificial; Prosthesis Implantation; Thrombosis; Time Factors; Treatment Outcome; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Drug Hypersensitivity; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Thrombin Time; Thrombosis; Time Factors | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
Topics: Administration, Oral; Age Factors; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Child; Child, Preschool; Dabigatran; Drug Compounding; Drug Monitoring; Female; Hemorrhage; Humans; Infant; Male; Pulmonary Embolism; Recurrence; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2017 |
Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Stroke; Time Factors; Warfarin | 2018 |
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Topics: Administration, Oral; Age Factors; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Compounding; Drug Monitoring; Female; France; Hemorrhage; Humans; Infant; Linear Models; Male; Nonlinear Dynamics; Ontario; Pharmaceutical Solutions; Russia; Treatment Outcome; Venous Thromboembolism | 2017 |
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Canada; Cardiac Surgical Procedures; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Perioperative Period; Postoperative Complications; Precision Medicine; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban | 2017 |
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Topics: Acute Disease; Anticoagulants; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Hemorrhage; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; Recurrence; Reference Standards; Research Design; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2018 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Bacteremia; Belgium; Blood Coagulation; Coagulase; Dabigatran; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Thrombin; Thrombosis; Time Factors; Treatment Outcome | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Omeprazole; Perioperative Period; Peripheral Arterial Disease; Placebo Effect; Proton Pump Inhibitors; Stroke; Thrombosis; Treatment Outcome; Troponin; Venous Thromboembolism | 2018 |
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time | 2019 |
Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Regression Analysis; Rivaroxaban; Severity of Illness Index; Stroke | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Perioperative Period; Prospective Studies; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Intracranial Embolism; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke | 2019 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2013 |
Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Topics: Aged; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Female; Genome-Wide Association Study; Hemorrhage; Humans; Male; Polymorphism, Single Nucleotide; Prodrugs; Pyridines | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Stroke; Treatment Outcome | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Stroke; Thromboembolism; Warfarin | 2013 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes Mellitus; Embolism; Female; Hemorrhage; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Stroke | 2014 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrhage; Humans; Software; Thromboembolism; Warfarin | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Blood Loss, Surgical; Clinical Protocols; Coagulants; Dabigatran; Hemorrhage; Humans; Research Design; Treatment Outcome | 2015 |
Idarucizumab for Dabigatran Reversal.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Thrombosis | 2015 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Rivaroxaban; Ultrasonography, Doppler; Venous Thrombosis | 2015 |
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Topics: Aged; Asian People; Creatinine; Dabigatran; Embolism; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Stroke; Warfarin | 2015 |
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Double-Blind Method; Female; Health Services; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Pulmonary Embolism; Quality-Adjusted Life Years; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2016 |
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
Topics: Aged; Anticoagulants; Antithrombins; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Risk; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Hemorrhage; Humans; Intracranial Embolism; Prospective Studies; Pulmonary Veins; Research Design | 2016 |
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Dabigatran; Female; Hemorrhage; Humans; Interleukin-6; Male; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Stroke; Thromboembolism; Warfarin | 2015 |
Ablation perioperative dabigatran in use envisioning in Japan: The ABRIDGE-J Study Design.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Thromboembolism; Warfarin | 2016 |
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Disease Management; Female; Hemorrhage; Humans; Male; Warfarin | 2016 |
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Topics: Administration, Oral; Anticoagulants; Arrhythmias, Cardiac; Canada; Cause of Death; Dabigatran; Defibrillators, Implantable; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Pacemaker, Artificial; Practice Guidelines as Topic; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2016 |
Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Insufficiency; Treatment Outcome; Venous Thromboembolism | 2016 |
Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Warfarin | 2016 |
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Data Interpretation, Statistical; Decision Making; Female; Hemorrhage; Humans; Male; Models, Statistical; Regression Analysis; Risk Factors; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Venous Thromboembolism; Warfarin; Young Adult | 2016 |
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Protocols; Coronary Artery Disease; Coronary Thrombosis; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome; Warfarin | 2016 |
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Blood Transfusion; Cost-Benefit Analysis; Dabigatran; Emergencies; Female; Hemorrhage; Hemostatics; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Models, Econometric; Prospective Studies; Time Factors | 2017 |
Effects of dabigatran according to age in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Netherlands; Ontario; Risk Assessment; Risk Factors; Stroke; Survival Rate; Sweden; Time Factors; United States | 2017 |
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antithrombins; Blood Coagulation; Dabigatran; Double-Blind Method; Epitopes; Healthy Volunteers; Hemorrhage; Humans; Luminescence; Middle Aged; Renal Insufficiency; Treatment Outcome; Young Adult | 2017 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Dyspepsia; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Liver; Male; Middle Aged; Myocardial Infarction; Prodrugs; Proportional Hazards Models; Pyridines; Stroke; Warfarin | 2009 |
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Electric Stimulation Therapy; Hemorrhage; Humans; Incidence; Retrospective Studies; Stroke; Warfarin | 2011 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Survival Analysis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Stroke; Warfarin | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Factors; Time Factors; Warfarin | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Warfarin | 2011 |
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain Ischemia; Cardiac Pacing, Artificial; Cataract Extraction; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Risk Factors; Stroke; Thromboembolism; Warfarin | 2012 |
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Prodrugs; Pyridines; Safety; Thrombin; Thromboembolism; Venous Thrombosis | 2004 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Enzyme Tests; Dabigatran; Double-Blind Method; Drug Administration Routes; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Postoperative Complications; Prodrugs; Pyridines; Treatment Outcome; Venous Thrombosis | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Pyridines; Thromboembolism; Venous Thrombosis | 2007 |
629 other study(ies) available for dabigatran and Bleeding
| Article | Year |
|---|---|
Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Rivaroxaban; Taiwan; Venous Thromboembolism | 2021 |
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles | 2021 |
Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Hemorrhage; Humans; Hypertension; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke | 2022 |
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Bariatric Surgery; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Thrombosis | 2022 |
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Heart Failure; Hemorrhage; Humans | 2022 |
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device.
Topics: Administration, Oral; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke; Thrombosis; Treatment Outcome; Warfarin | 2022 |
A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; China; Dabigatran; Female; Hemorrhage; Hospitals; Humans; Inappropriate Prescribing; Male; Middle Aged; Retrospective Studies; Risk Factors; Rivaroxaban | 2021 |
Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Thrombosis | 2022 |
Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thrombosis | 2021 |
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Sex Factors; Stroke; Thromboembolism; Turkey | 2021 |
Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Machine Learning; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Embolism; Hemorrhage; Humans; Risk Factors; Stroke; Warfarin | 2022 |
Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Charcoal; Cohort Studies; Dabigatran; Eating; Hemorrhage; Humans; Middle Aged; Pyridones; Rivaroxaban | 2022 |
A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia.
Topics: Administration, Oral; Adult; Anticoagulants; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Thrombocytopenia; Thrombosis | 2022 |
Topics: Dabigatran; Hemorrhage; Humans; Rivaroxaban | 2022 |
Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Interactions; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban | 2023 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |
Four cases of hemorrhagic herpes zoster associated with dabigatran therapy.
Topics: Dabigatran; Hemorrhage; Herpes Zoster; Herpesvirus 3, Human; Humans | 2022 |
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Registries; Stroke; Vitamin K | 2022 |
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Pyridones; Registries; Rivaroxaban; Stroke | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Frequency of hemorrhage after tooth extraction in patients treated with a direct oral anticoagulant: A multicenter cross-sectional study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Male; Prospective Studies; Pyridones; Rivaroxaban; Tooth Extraction; Warfarin | 2022 |
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.
Topics: Anticoagulants; Asian People; Atorvastatin; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Rivaroxaban; Simvastatin; Singapore; Stroke | 2023 |
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Japan; Stroke | 2022 |
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Overweight; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Direct oral anticoagulants toxicity in children: an overview and practical guide.
Topics: Administration, Oral; Anticoagulants; Charcoal; Child; Dabigatran; Hemorrhage; Hemostatics; Humans; Vitamin K | 2022 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; France; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
An Overview of Thrombin Inhibitors in the Perspective of Structureactivity Relationships.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Thrombin; Thrombosis | 2023 |
Understanding variation in the results of real-world evidence studies that seem to address the same question.
Topics: Dabigatran; Hemorrhage; Humans; Warfarin | 2022 |
[Reversal of direct oral anticoagulants: what about new treatments available?]
Topics: Administration, Oral; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Recombinant Proteins | 2022 |
Protocolized management of bleeding in hospitals in The Netherlands in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Hospitals; Humans; Netherlands; Pyridones; Rivaroxaban | 2023 |
[Reversal agents for severe bleeding associated with direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Rivaroxaban; Vitamin K | 2022 |
Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fibrinogen; Hemorrhage; Humans; Kaolin; Male; Pyridones; Rivaroxaban; Thrombelastography | 2022 |
Bleeding risk of oral anticoagulants in liver cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Liver Cirrhosis; New Zealand; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Hypertension; Male; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2022 |
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2022 |
[Dabigatran Reversal: A Practical Approach].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans | 2022 |
Protocols for perioperative management of direct oral anticoagulants in hospitals: opportunities for improvement.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Hospitals; Humans; Pyridones; Rivaroxaban | 2023 |
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; ATP Binding Cassette Transporter, Subfamily B; Atrial Fibrillation; Carboxylic Ester Hydrolases; Dabigatran; Hemorrhage; Humans; Polymorphism, Single Nucleotide; Prospective Studies | 2022 |
Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Predictors of use of direct oral anticoagulants in acute pulmonary embolism.
Topics: Acute Disease; Anticoagulants; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pulmonary Embolism; Rivaroxaban | 2022 |
Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study.
Topics: Atrial Fibrillation; China; Dabigatran; Hemorrhage; Humans; Polymorphism, Single Nucleotide; Prospective Studies | 2022 |
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study.
Topics: Administration, Oral; Aged; Anticoagulants; Bevacizumab; Dabigatran; Female; Hemorrhage; Humans; Neoplasms; Pulmonary Embolism; Retrospective Studies; Rivaroxaban | 2022 |
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Propensity Score; Rivaroxaban; Stroke | 2023 |
Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
Topics: Administration, Oral; Anticoagulants; Child; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2023 |
Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-treated Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Dizziness; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Syncope | 2023 |
Direct oral anticoagulants and warfarin safety in rural patients with obesity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Retrospective Studies; Rural Population; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran.
Topics: Atrial Fibrillation; Bayes Theorem; Dabigatran; Decision Trees; Hemorrhage; Humans; Machine Learning | 2023 |
Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Dementia; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; United States; Warfarin | 2023 |
Reversal agents for current and forthcoming direct oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Recombinant Proteins; Rivaroxaban; Vitamin K | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Hypertension; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2023 |
Adherence to protocols for the use of reversal agents in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Protocols; Dabigatran; Hemorrhage; Humans; Recombinant Proteins; Retrospective Studies | 2023 |
Direct oral anticoagulants: patient reported adherence and minor bleedings.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Patient Reported Outcome Measures; Pyridones; Rivaroxaban; Stroke | 2023 |
Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
[Increased menstrual bleeding among direct oral anticoagulant users].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Rivaroxaban | 2023 |
Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Delivery of Health Care; Hemorrhage; Humans; Male; Prevalence; Pyridones; Rivaroxaban; Stroke | 2023 |
OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants.
Topics: Administration, Oral; Animals; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Rabbits; Rats; Rivaroxaban; Thrombin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.
Topics: Antithrombins; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Thromboembolism | 2023 |
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Prospective Studies; Stroke; Vitamins | 2023 |
Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Stroke | 2023 |
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Embolism; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report.
Topics: Acute Kidney Injury; Administration, Oral; Aged, 80 and over; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Male; Pyridones | 2023 |
Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Safety and efficacy of oral anticoagulants in extreme weights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Thinness; Venous Thromboembolism; Warfarin | 2023 |
Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; End Stage Liver Disease; Hemorrhage; Humans; Liver Cirrhosis; Portal Vein; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Venous Thrombosis | 2023 |
Benefits and Harms of Standard Versus Reduced-Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Morbidity; Retrospective Studies; Rivaroxaban; Stroke; United States | 2023 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles | 2019 |
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Asia, Southeastern; Cross-Sectional Studies; Dabigatran; Drug Utilization; Europe; Female; Hemorrhage; Humans; International Cooperation; Male; Middle Aged; North America; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Young Adult | 2020 |
Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Leukocyte Count; Male; Middle Aged; Proportional Hazards Models | 2019 |
[Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Primary Health Care; Propensity Score; Stroke; Thromboembolism; Vitamin K | 2020 |
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Treatment Outcome | 2019 |
Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Blood Loss, Surgical; Dabigatran; Emergencies; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Surgical Procedures, Operative | 2021 |
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; New Zealand; Retrospective Studies; Treatment Outcome | 2019 |
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; France; Hemorrhage; Humans; Myocardial Infarction; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
Topics: Antithrombins; Atrial Fibrillation; Cause of Death; Cohort Studies; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Incidence; Myocardial Infarction; Prospective Studies; Registries; Stroke; Time Factors; Treatment Outcome | 2019 |
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin; Young Adult | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2020 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Warfarin | 2020 |
[Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cause of Death; Comorbidity; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2020 |
Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Stroke; Time Factors; Treatment Outcome | 2020 |
Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Off-Label Use; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; United States | 2020 |
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants.
Topics: Aged; Aged, 80 and over; Dabigatran; Emergency Service, Hospital; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Registries; Warfarin | 2020 |
Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Hemorrhage; Humans; Pharmaceutical Preparations; Pyridones; Rivaroxaban | 2020 |
Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Japan; Male; Middle Aged; Population Surveillance; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2020 |
Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Prospective Studies; Renal Elimination; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2020 |
Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Europe; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Israel; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Protective Factors; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vitamin K; Young Adult | 2020 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Antithrombins; Brain Ischemia; Cause of Death; Comorbidity; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Myocardial Revascularization; Ontario; Procedures and Techniques Utilization; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Thrombophilia; Vitamin K | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2020 |
Assessment of direct oral anticoagulants administered as potentially inappropriate medications to elderly inpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; China; Creatinine; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Inappropriate Prescribing; Inpatients; Length of Stay; Male; Polypharmacy; Retrospective Studies; Risk Factors; Rivaroxaban; Thromboembolism | 2020 |
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Stroke; Vitamin K | 2020 |
A Life-threatening Combination: Indomethacin and Dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Indomethacin | 2020 |
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban | 2020 |
Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.
Topics: Anticoagulants; China; Dabigatran; Drug Interactions; Hemorrhage; Humans; Models, Theoretical; Risk Factors; Ticagrelor | 2020 |
Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Chest Tubes; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Middle Aged; Pneumothorax; Respiratory Insufficiency; Rivaroxaban; Thoracostomy; Treatment Outcome | 2020 |
[TEG-guided treatment of a dabigatran overdose in a patient with acute kidney failure].
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Male; Renal Dialysis; Thrombelastography | 2020 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Topics: Administration, Oral; Aged; Anticoagulants; Bioprosthesis; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thromboembolism; Warfarin | 2020 |
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Male; Rivaroxaban; Spain; Stroke; Vitamin K | 2021 |
Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation Factors; Dabigatran; Hemorrhage; Hemostasis; Hemostatics; Humans; Retrospective Studies; Rivaroxaban | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke | 2020 |
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.
Topics: Aged; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Perioperative Care; Pyrazoles; Pyridones; Risk Adjustment; Rivaroxaban; Stroke | 2020 |
Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Renal Replacement Therapy | 2022 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
Diastolic blood pressure achieved at target systolic blood pressure (120-140 mm Hg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: A real-world study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Dabigatran; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged | 2020 |
Postpolypectomy bleeding of colorectal polyps in patients with continuous warfarin and short-term interruption of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Colonic Polyps; Dabigatran; Hemorrhage; Humans; Male; Pyridones; Rivaroxaban; Warfarin | 2021 |
Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Tandem Mass Spectrometry; Thrombosis; Treatment Outcome | 2020 |
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cobicistat; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Risk Assessment; Ritonavir | 2021 |
Dabigatran reversal with idarucizumab prior to lung transplantation.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Hemorrhage; Humans; Lung Transplantation; Retrospective Studies | 2021 |
Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Warfarin; Young Adult | 2020 |
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2021 |
The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; ATP Binding Cassette Transporter, Subfamily B; Atrial Fibrillation; Carboxylic Ester Hydrolases; Dabigatran; Hemorrhage; Humans; Polymorphism, Genetic; Prospective Studies | 2021 |
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; China; Creatinine; Dabigatran; Drug Administration Schedule; Drug Monitoring; Female; Hemorrhage; Humans; Male; Partial Thromboplastin Time | 2021 |
Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.
Topics: Aged; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index | 2021 |
Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Mortality; Propensity Score; Pyrazoles; Pyridones; Stroke; Warfarin | 2021 |
Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.
Topics: Antithrombins; Biological Availability; Chemical Precipitation; Dabigatran; Drug Compounding; Drug Development; Drug Substitution; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Stroke; Pharmacokinetics; Safety; Treatment Outcome | 2021 |
Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Recombinant Proteins | 2021 |
Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Regression Analysis; Rivaroxaban; Warfarin | 2021 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2021 |
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolic Stroke; Hemorrhage; Humans; Ischemic Stroke; Models, Economic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
Thromboelastography utilization for dabigatran reversal in a patient with acute kidney injury.
Topics: Acute Kidney Injury; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Thrombelastography | 2021 |
[Is one DOAC better than another?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Thromboembolism; Treatment Outcome | 2021 |
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Stroke; Treatment Outcome | 2021 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Treatment Outcome | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyridones; Registries; Rivaroxaban | 2022 |
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.
Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism | 2021 |
Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin.
Topics: Administration, Oral; Anticoagulants; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2022 |
[Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Dabigatran; Drug Overdose; Hemorrhage; Humans; Male; Middle Aged; Thrombelastography | 2017 |
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Chi-Square Distribution; Comparative Effectiveness Research; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medicare Part D; Multivariate Analysis; Patient Admission; Propensity Score; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Treatment Outcome; United States; Warfarin | 2017 |
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Cohort Studies; Dabigatran; Europe; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban | 2017 |
Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Liver; Male; Sus scrofa | 2017 |
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Administration Schedule; Fatal Outcome; Gastrointestinal Hemorrhage; Hemofiltration; Hemorrhage; Humans; Male; Renal Dialysis; Renal Replacement Therapy; Sepsis | 2017 |
Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Renal Insufficiency; Severity of Illness Index; Time Factors | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation.
Topics: Dabigatran; Heart-Assist Devices; Hemorrhage; Humans; Pilot Projects; Vitamin K | 2017 |
Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; End Stage Liver Disease; Hemorrhage; Humans; Male; Patient Care Management; Risk Adjustment; Risk Assessment; Stroke; Treatment Outcome | 2018 |
Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Thromboembolism; Time Factors; Treatment Outcome | 2017 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Expenditures; Health Resources; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Warfarin | 2017 |
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism | 2017 |
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Hospitalization; Humans; Male; Patient Acceptance of Health Care; Patient Readmission; Retrospective Studies; Stroke; United States; Warfarin | 2019 |
Thrombocytopenia induced by dabigatran: two case reports.
Topics: Aged; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Thrombocytopenia; Thromboembolism; Warfarin | 2017 |
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Substitution; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2018 |
Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Incomplete dabigatran reversal with idarucizumab.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Treatment Outcome | 2018 |
Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Clinical Trials as Topic; Dabigatran; Half-Life; Hemorrhage; Humans; Partial Thromboplastin Time; Rats; Swine; Thrombin Time | 2017 |
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Decision Making; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Female; Hemorrhage; Hong Kong; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Patient Readmission; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2017 |
New oral anticoagulant prescription rate and risk of bleeding in an Italian region.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cross-Over Studies; Dabigatran; Drug Prescriptions; Female; Hemorrhage; Hospitalization; Humans; Italy; Male; Middle Aged; Prevalence; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Time Factors | 2017 |
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Embolism; Female; Hemorrhage; Hospital Charges; Humans; Male; Middle Aged; Netherlands; Propensity Score; Retrospective Studies; Sex Factors; Stroke | 2017 |
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Follow-Up Studies; Health Care Costs; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stroke; Warfarin | 2017 |
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
[Use of a Delphi survey to assess the hospital economic impact of innovative products: The example of idarucizumab a dabigatran-specific reversal agent].
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Delphi Technique; Drug Costs; Economics, Hospital; France; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Surveys and Questionnaires | 2017 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2017 |
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Warfarin | 2017 |
Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Hemostasis; Humans; Male; Multiple Trauma; Random Allocation; Swine | 2017 |
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke | 2018 |
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.
Topics: Administration, Oral; Adult; Age Factors; Aged; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis | 2017 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Turkey | 2018 |
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; France; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Medication Adherence; Middle Aged; Rivaroxaban; Stroke; Vitamin K | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Blood Loss, Surgical; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Risk Factors; Severity of Illness Index; Taiwan | 2018 |
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Propensity Score; Retrospective Studies; Stroke; Warfarin | 2017 |
Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Malaysia; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke | 2017 |
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiovascular Diseases; Clinical Decision-Making; Dabigatran; Drug Monitoring; Drug Resistance; Factor Xa Inhibitors; Focus Groups; General Practitioners; Hemorrhage; Humans; Medical Staff, Hospital; Medication Adherence; Norway; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Qualitative Research; Risk; Rivaroxaban; Warfarin | 2018 |
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Anticoagulants; Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?
Topics: Animals; Antithrombins; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Hemorrhage; Humans; Mass Spectrometry; Sensitivity and Specificity; Venous Thromboembolism | 2017 |
Reversal Strategies for Newer Oral Anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; United States | 2017 |
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Survival Rate; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2017 |
After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy.
Topics: Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention | 2017 |
Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
Topics: Adult; Aged; Atrial Fibrillation; Cohort Studies; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Prospective Studies; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Angiography; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Patient Safety; Phenindione; Propensity Score; Proportional Hazards Models; Risk; Treatment Outcome; Vitamin K | 2018 |
Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Middle Aged; Myocardial Infarction; Patient Acceptance of Health Care; Retrospective Studies; Stroke; United States; Warfarin | 2018 |
Hemorrhagic pleuropericardial effusion secondary to dabigatran.
Topics: Aged, 80 and over; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Obesity; Pericardial Effusion; Pericardial Window Techniques; Pleural Effusion | 2018 |
[Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Risk Factors | 2017 |
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Synergism; Hemorrhage; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Taiwan | 2018 |
[Angiology and haemostasis. Highlights on some new data in 2017].
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Hemostasis; Humans; Venous Thromboembolism | 2018 |
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2018 |
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke.
Topics: Aged; Anticoagulants; Brain Ischemia; Chagas Cardiomyopathy; Dabigatran; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Stroke; Warfarin | 2018 |
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Hemorrhage; Humans; Middle Aged; Neoplasms; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult | 2018 |
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Dabigatran; Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Survival Analysis; Venous Thrombosis; Warfarin | 2018 |
Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain Ischemia; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Models, Biological; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Young Adult | 2018 |
Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Propensity Score; Retrospective Studies; Rivaroxaban; Warfarin | 2018 |
Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Topics: Administration, Intravenous; Animals; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Hemorrhage; Infusions, Intraosseous; Male; Multiple Trauma; Swine | 2018 |
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Warfarin; Withholding Treatment; Young Adult | 2018 |
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Models, Statistical; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2018 |
Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Male; Pulmonary Alveoli; Treatment Outcome | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
Topics: Adult; Aged; Anticoagulants; Benzimidazoles; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Female; Hemorrhage; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Plasma; Recombinant Proteins; Rivaroxaban; Thrombin | 2018 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Patient Discharge; Pulmonary Embolism; Quebec; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2018 |
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Registries; Rivaroxaban; Treatment Outcome; Ventricular Fibrillation | 2018 |
Management of Dabigatran-associated bleeding in two elderly patients with acute renal failure.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Dabigatran; Female; Hemorrhage; Humans | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Quebec; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Australia; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Renal Insufficiency; Retrospective Studies; Thrombin Time | 2019 |
Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Dementia; Dicumarol; Disabled Persons; Follow-Up Studies; Hemorrhage; Humans; Mobility Limitation; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2018 |
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome | 2018 |
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.
Topics: Anticoagulants; Computer Simulation; Confounding Factors, Epidemiologic; Dabigatran; Data Interpretation, Statistical; Epidemiologic Research Design; Hemorrhage; Humans; Propensity Score; Risk Assessment; Stroke; Warfarin | 2018 |
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Safety; Primary Health Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dabigatran; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Management of dabigatran after overdosage: two case reports and suggestions for monitoring.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Drug Overdose; Emergency Treatment; Hemorrhage; Humans | 2018 |
Updated French practical guidelines on the management of dabigatran-treated patients.
Topics: Anticoagulants; Dabigatran; Emergencies; Hemorrhage; Hemostasis; Humans | 2018 |
Perioperative coagulation management: Evolving strategies.
Topics: Blood Coagulation; Dabigatran; Hemorrhage; Hemostasis; Humans | 2018 |
Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Emergency Medical Services; Female; Hemorrhage; Humans; Spinal Puncture | 2019 |
Assessment of patients post reversal with idarucizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Drug Interactions; Hemorrhage; Hemostasis; Humans; Thromboembolism; Thrombosis; Time Factors; Treatment Outcome | 2018 |
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2018 |
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Obesity, Morbid; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2019 |
Anticoagulant-associated adverse drug reactions in 2013-15.
Topics: Age Distribution; Anticoagulants; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Distribution; Time Factors; Warfarin | 2018 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate.
Topics: Anticoagulants; Aptamers, Nucleotide; Atrial Fibrillation; Dabigatran; Embolism; Gene Library; Hemorrhage; Humans; Ligands; SELEX Aptamer Technique; Sensitivity and Specificity; Stroke | 2018 |
Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Hemorrhage; Hemostasis; Humans; Intracranial Hemorrhages; Male; Middle Aged; Thrombosis; Treatment Outcome | 2019 |
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Humans; Male; Medicare; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2019 |
Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stroke; Thromboembolism; Treatment Outcome | 2018 |
In myocardial injury after noncardiac surgery, dabigatran reduced vascular events without increasing major bleeding.
Topics: Dabigatran; Hemorrhage; Humans; Myocardial Infarction | 2018 |
Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Decision-Making; Dabigatran; Female; Hemorrhage; Hemostasis; Humans; Male; Netherlands; Patient Selection; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Blood Coagulation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Logistic Models; Male; Multivariate Analysis; Partial Thromboplastin Time; Predictive Value of Tests; Retrospective Studies; ROC Curve | 2019 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles | 2018 |
Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Medicare; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Secondary Prevention; Skilled Nursing Facilities; Stroke; Thromboembolism; United States | 2018 |
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; Vitamin K | 2019 |
Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Drug Interactions; Hemorrhage; Humans; Quinidine; Thrombin Time | 2019 |
Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Coagulants; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Young Adult | 2019 |
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Embolism; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2019 |
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Military Medicine; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Defense; Young Adult | 2019 |
Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Retrospective Studies; Rivaroxaban; Thrombelastography; Treatment Outcome | 2019 |
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemodynamics; Hemorrhage; Male; Multiple Trauma; Swine; Thrombin | 2019 |
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome | 2019 |
A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Cross-Over Studies; Cytochrome P-450 CYP3A; Dabigatran; Drug Interactions; Electronic Health Records; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rhabdomyolysis | 2019 |
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2019 |
Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles | 2019 |
Reversal strategies in patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Humans; Rivaroxaban | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Stroke; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Statins and the risk of bleeding in patients taking dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Polypharmacy; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke | 2019 |
Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States; Warfarin; Young Adult | 2019 |
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Brazil; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2019 |
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Topics: Aged; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Pilot Projects; Probability; Propensity Score; Thromboembolism; Treatment Outcome; Vitamin K | 2019 |
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Withholding Treatment | 2019 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Secondary Bleeding During Acute Experimental Intracerebral Hemorrhage.
Topics: Acute Disease; Animals; Anticoagulants; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Male; Mice; Random Allocation; Warfarin | 2019 |
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Treatment Outcome | 2019 |
Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Critical Care; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Intracranial Hemorrhages; Thrombolytic Therapy | 2019 |
Deprivation and inequalities lead to worse outcomes with dabigatran etexilate.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; New Zealand; Proportional Hazards Models; Retrospective Studies; Risk Factors; Socioeconomic Factors; Statistics, Nonparametric; Stroke; Thromboembolism; Treatment Outcome; White People | 2018 |
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Decision Making, Shared; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2019 |
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Australia; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Myocardial Infarction; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Veterans; Warfarin | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Use of idarucizumab in clinical practice: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Budd-Chiari Syndrome; Dabigatran; Hemorrhage; Humans; Liver Transplantation | 2019 |
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; United States Department of Defense; Warfarin; Young Adult | 2019 |
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Republic of Korea; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke; Warfarin; Young Adult | 2019 |
Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes.
Topics: Administration, Oral; Algorithms; Anticoagulants; Asymptomatic Infections; Atrial Fibrillation; Computer Simulation; Dabigatran; Hemorrhage; Humans; Likelihood Functions; Meta-Analysis as Topic; Motivation; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2020 |
RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures.
Topics: Ablation Techniques; Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Treatment Outcome | 2018 |
Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR).
Topics: Antibodies, Monoclonal, Humanized; Brain Ischemia; Dabigatran; Emergency Medical Services; Germany; Hemorrhage; Humans; Registries; Stroke | 2019 |
Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Male; Plasma; Renal Dialysis; Treatment Outcome | 2019 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Catheter Ablation; Critical Illness; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Infusions, Intravenous; Intraoperative Complications; Male; Preoperative Care; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2013 |
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Prospective Studies; Stroke; Warfarin | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Agents; Dabigatran; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome; Withholding Treatment | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Research Design; Stroke; Warfarin | 2013 |
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung Diseases; Male; Renal Dialysis; Treatment Outcome | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Female; Hemorrhage; Humans; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Retrospective Studies; Risk Factors; Stroke | 2013 |
Dabigatran and bleeding: still an emergent situation?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Factor VIII; Hemorrhage; Humans; Prothrombin; Recombinant Proteins; Renal Dialysis | 2013 |
Uncontrollable haemorrhage following dabigatran prophylaxis.
Topics: Abdomen; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Medical Services; Hemorrhage; Humans; Laparotomy; Male; Treatment Outcome | 2013 |
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Indicators and Reagents; Male; Middle Aged; Partial Thromboplastin Time; Thrombin; Thrombin Time | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Postoperative Complications; Thrombosis; Warfarin | 2013 |
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Capsules; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Dyspepsia; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Interviews as Topic; Male; Medication Adherence; Patient Education as Topic; Risk Factors; Stroke; Time Factors | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebrovascular Disorders; Clopidogrel; Comorbidity; Dabigatran; Drug Synergism; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Models, Cardiovascular; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticlopidine; Treatment Outcome | 2013 |
[New anticoagulants, new emergencies?].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Warfarin | 2013 |
Dabigatran monitoring made simple?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Partial Thromboplastin Time; Reference Values; Regression Analysis; Research Design; Risk; Thrombin; Time Factors | 2013 |
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Device Removal; Drug Administration Schedule; Electric Countershock; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Prosthesis Implantation; Reoperation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2013 |
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; Hemorrhage; Humans; Male; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Thiophenes | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Reversal of a dabigatran overdose: what are possible options?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Hemorrhage; Humans; Prothrombin; Recombinant Proteins; Renal Dialysis | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assessment; Stroke; Thrombosis; Warfarin | 2013 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Hemorrhage; Kidney; Kidney Glomerulus; Male; Rats; Rats, Sprague-Dawley; Warfarin | 2014 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Fatal bleeding associated with dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Dabigatran; Fat Emulsions, Intravenous; Hemorrhage; Male; Rats; Rats, Sprague-Dawley | 2013 |
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Female; Half-Life; Hemorrhage; Humans; Kidney Diseases; Male; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Warfarin | 2013 |
Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Emergency Medical Services; Emergency Service, Hospital; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male | 2013 |
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2014 |
Emergency abdominal surgery in a patient anticoagulated with dabigatran.
Topics: Abdominal Injuries; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Medical Services; Female; Hemorrhage; Hemostasis; Humans; Laparoscopy | 2013 |
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Comorbidity; Dabigatran; Drug Dosage Calculations; Drug Substitution; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Education as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Registries; Risk Factors; Socioeconomic Factors; Stroke; Time Factors; Treatment Outcome; United States | 2013 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Diabetes Mellitus; Drug Therapy, Combination; Factor IX; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Risk Assessment; Risk Factors; Smoking; Vitamin K; Warfarin | 2013 |
Evaluation of dabigatran exposures reported to poison control centers.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Child; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Poison Control Centers; Retrospective Studies | 2014 |
Dabigatran Use in the Real World: A Multihospital System Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Retrospective Studies | 2014 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Stroke; Survival Analysis; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
[Experience with rivaroxaban and dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Morpholines; Protein C Deficiency; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in singapore.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Consensus; Dabigatran; Hemorrhage; Humans; Singapore; Thiophenes | 2013 |
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Diabetes Mellitus, Type 2; Drug Overdose; Hemorrhage; Humans; Hyperkalemia; Male; Neoplasms; Phlebitis; Renal Dialysis | 2014 |
Activated prothrombin complex concentrate for dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Female; Hematoma, Subdural; Hemorrhage; Humans; Male; Prothrombin; Tomography, X-Ray Computed | 2014 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Female; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Renal Insufficiency; Stroke | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Warfarin | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Substitution; Early Termination of Clinical Trials; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Mitral Valve; Myocardial Infarction; Off-Label Use; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Vitamin K | 2014 |
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Brain; Brain Injuries; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Mice; Mice, Inbred C57BL; Warfarin | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Male | 2014 |
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; United States; United States Food and Drug Administration; Warfarin | 2014 |
Lessons from the RE-ALIGN trial.
Topics: Aged; Anticoagulants; Benzimidazoles; Bioprosthesis; Clinical Trials, Phase II as Topic; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial Infarction; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Thromboembolism; Warfarin | 2014 |
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
Topics: Animals; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Humans; Pyridines; Rats; Rats, Wistar; Tail; Treatment Outcome | 2014 |
Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation.
Topics: Animals; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Humans; Pyridines | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Retrospective Studies; Risk Factors; Stroke; Treatment Outcome; United States; United States Department of Veterans Affairs | 2014 |
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor VIIa; Hemorrhage; Humans | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Multiple-site bleeding with prominent rise in coagulation tests in an elderly woman using dabigatran etexilate.
Topics: Aged, 80 and over; Antithrombins; Dabigatran; Diagnosis, Differential; Female; Hemorrhage; Hemostatic Disorders; Humans | 2014 |
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Morpholines; Prospective Studies; Pyridines; Rivaroxaban; Thiophenes | 2014 |
Dabigatran: how the drug company withheld important analyses.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Industry; Drug Monitoring; Europe; Hemorrhage; Humans; United States; United States Food and Drug Administration | 2014 |
The trouble with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2014 |
Concerns over data in key dabigatran trial.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Approval; Drug Industry; Drug Monitoring; Hemorrhage; Humans; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2014 |
Dabigatran, bleeding, and the regulators.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Europe; Hemorrhage; Humans; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 2014 |
Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Disclosure; Drug Administration Schedule; Drug Industry; Hemorrhage; Humans; Information Dissemination; Patient Safety; Pyridines; Stroke | 2014 |
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2015 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Hong Kong; Humans; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome | 2014 |
Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Hemorrhage; Hemostatics; Prothrombin; Rabbits; Risk Assessment; Risk Factors; Thrombin; Time Factors; Venous Thrombosis | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Substitution; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; International Normalized Ratio; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Stroke; United States; United States Department of Veterans Affairs; Warfarin | 2014 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran: patient management in specific clinical settings.
Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Practice Guidelines as Topic; Venous Thromboembolism | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hemorrhage; Hospitals, General; Humans; Italy; Male; Middle Aged; Retrospective Studies | 2014 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
[Life-threatening bleeding during dabigatran treatment because of acute renal failure].
Topics: Acute Kidney Injury; Antithrombins; Critical Illness; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans; Middle Aged | 2014 |
[Serious bleeding as a consequence of accumulation of dabigatran caused by renal failure].
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Male; Renal Dialysis; Renal Insufficiency | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk; United States; Warfarin | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Safety of dabigatran in an elderly population: single center experience in Italy.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Fibrinolytic Agents; Heartburn; Hemorrhage; Humans; Italy; Male; Middle Aged; Patient Compliance; Prospective Studies; Registries; Risk Factors; Stroke; Thromboembolism | 2015 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Sex Factors; Stroke | 2015 |
Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Renal Dialysis | 2015 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Managed Care Programs; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Stroke; United States | 2014 |
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Young Adult | 2015 |
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Prothrombin; Reproducibility of Results; Risk Assessment; Russia; Stroke; Thromboembolism; Treatment Outcome | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Hemorrhage; Hemostasis; Humans; Saphenous Vein; Thrombelastography; Thrombin | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
Real-world variability in dabigatran levels in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Dosage Calculations; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Factors; Time Factors; Treatment Outcome | 2015 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Heparin; Humans; Lower Extremity; Male; Middle Aged; Severity of Illness Index; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Warfarin | 2014 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Comorbidity; Dabigatran; Denmark; Drug Prescriptions; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Cerebral Hemorrhage; Dabigatran; Drug Monitoring; Fatal Outcome; Female; Half-Life; Hemorrhage; Humans; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Renal Replacement Therapy; Time Factors; Treatment Outcome | 2015 |
What is the role of hemodialysis for dabigatran-associated major bleeding?
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Observational Studies as Topic; Renal Dialysis | 2014 |
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Defibrillators, Implantable; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Embolism; Female; Germany; Hemorrhage; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2015 |
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Contraindications; Dabigatran; Drug Therapy, Combination; Germany; Hemorrhage; Humans; Male; Risk Factors; Stents; Ticlopidine | 2015 |
[Antidote to dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Risk Factors; Thrombosis | 2015 |
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Topics: Aged; Amiodarone; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dronedarone; Female; Glomerular Filtration Rate; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2015 |
Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.
Topics: Aged; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Warfarin | 2015 |
Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kidney; Male; Middle Aged; Odds Ratio; United States; United States Food and Drug Administration; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Perioperative Management of Dabigatran: A Prospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Disease Management; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Thromboembolism | 2015 |
Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Tandem Mass Spectrometry; Time Factors; Treatment Outcome | 2015 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Treatment Outcome; Warfarin | 2015 |
[Use of dabigatran etexilate for treatment of deep vein thrombosis and pulmonary artery thromboembolism].
Topics: Adult; Angiography; Benzimidazoles; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Echocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prodrugs; Prospective Studies; Pulmonary Embolism; Pyridines; Russia; Thrombophilia; Treatment Outcome; Venous Thrombosis | 2015 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Minnesota; Mohs Surgery; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Skin Diseases; Thiophenes | 2015 |
[Importance of appropiate clinical management of direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Spain; Venous Thromboembolism | 2016 |
Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors.
Topics: Animals; Antithrombins; Binding Sites; Crystallography, X-Ray; Dabigatran; Disease Models, Animal; Drug Design; Hemorrhage; Humans; Ligands; Mice; Molecular Docking Simulation; Molecular Mimicry; Platelet Aggregation; Protein Binding; Protein Conformation; Rabbits; Rats; Rats, Sprague-Dawley; Risk Assessment; Structure-Activity Relationship; Thrombin; Venous Thrombosis | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Europe; Female; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Logistic Models; Male; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban | 2015 |
Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Middle Aged; Risk; Rivaroxaban; Thromboembolism; Thrombophilia; Vitamin K; Warfarin; Young Adult | 2015 |
Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Fibrinolytic Agents; Hemorrhage; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Self Care; Stroke; Thrombosis; Vitamin K; Warfarin | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Hemorrhage; Humans; Kaplan-Meier Estimate; Models, Economic; Pulmonary Embolism; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Direct oral anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Drug Costs; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles | 2015 |
[First NOAK antidote soon to be approved].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Atrial Fibrillation; Dabigatran; Drug Approval; Hemorrhage; Humans; Infusions, Intravenous; Stroke; Time Factors | 2015 |
Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation.
Topics: Anticoagulants; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; International Normalized Ratio; Kinetics; Prosthesis Design; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Effect of Renal Function on Anticoagulation Therapy in Asian Patients.
Topics: Creatinine; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Stroke; Warfarin | 2015 |
Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Area Under Curve; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Blood Platelets; Calibration; Dabigatran; Femoral Fractures; Fibrin Fibrinogen Degradation Products; Hemodynamics; Hemorrhage; Hemostasis; Male; Multiple Trauma; Partial Thromboplastin Time; Platelet Aggregation; Platelet Function Tests; Prothrombin Time; Random Allocation; Swine; Thrombelastography; Thrombin; Time Factors; Vitamin K | 2016 |
[New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Utilization; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombophilia; Urban Health Services | 2016 |
[General practice study confirms a favorable risk benefit profile].
Topics: Atrial Fibrillation; Dabigatran; Drug Approval; General Practice; Hemorrhage; Humans; Risk Assessment; Warfarin | 2015 |
Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Male; Swine | 2015 |
Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
Topics: Animals; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Femur; Hemorrhage; Liver; Male; Multiple Trauma; Sodium Chloride; Swine | 2015 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Pulmonary Embolism; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thrombosis; Warfarin | 2015 |
Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Propensity Score; Risk Factors; Rivaroxaban; Treatment Outcome; Withholding Treatment | 2016 |
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Disease-Free Survival; Drug Evaluation; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Insurance Coverage; Kaplan-Meier Estimate; Male; Middle Aged; Military Personnel; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Evaluation; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Insurance Coverage; Male; Middle Aged; Myocardial Infarction; Polypharmacy; Propensity Score; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Direct oral anticoagulants and the bleeding patient.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antifibrinolytic Agents; Antithrombins; Blood Coagulation Factors; Charcoal; Dabigatran; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Tranexamic Acid; Warfarin | 2016 |
Conservative Management of Intentional Massive Dabigatran Overdose.
Topics: Aged, 80 and over; Antidotes; Antithrombins; Blood Coagulation Tests; Charcoal; Chromatography, Liquid; Dabigatran; Drug Monitoring; Gastric Lavage; Hemorrhage; Humans; Male; Plasma; Suicide, Attempted; Treatment Outcome | 2015 |
Report questions FDA approval of controversial anticoagulant.
Topics: Anticoagulants; Dabigatran; Drug Approval; Hemorrhage; Humans; Product Surveillance, Postmarketing; Stroke; United States | 2015 |
[The Use of Dabigatran for Prevention of Thromboembolic Complications in Patients Underwent Atrial Fibrillation Catheter Ablation].
Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Siberia; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Health Knowledge, Attitudes, Practice; Healthcare Disparities; Hemorrhage; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Quebec; Risk Assessment; Risk Factors; Sex Factors; Stroke; Treatment Outcome; Warfarin | 2015 |
Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Elective Surgical Procedures; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Perioperative Period; Prospective Studies; Prothrombin Time; Risk; Thrombin Time; Thromboembolism; Treatment Outcome | 2016 |
Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
Topics: Aged; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Middle Aged; Population Surveillance; Prevalence; Prospective Studies; Registries; Risk Factors; Stroke; Thromboembolism; Treatment Outcome | 2015 |
Emergency admissions for major haemorrhage associated with direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Gastrointestinal Hemorrhage; Hemodynamics; Hemorrhage; Hemostasis; Humans; Intracranial Hemorrhages; Male; Middle Aged; Patient Admission; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thrombosis | 2015 |
'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; New Zealand; Population Surveillance; Retrospective Studies; Risk Assessment; Survival Rate; Time Factors; Warfarin | 2016 |
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Cross-Over Studies; Dabigatran; Drug Substitution; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Rivaroxaban; Thiazoles; Young Adult | 2016 |
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2016 |
Letter to the Editor: Managing Dabigatran-Related Bleeding.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans | 2016 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2015 |
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K | 2017 |
Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD®.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Databases, Factual; Electrodes, Implanted; Equipment Design; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2016 |
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Case-Control Studies; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Stroke; Taiwan; Warfarin | 2016 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
Dental implant surgery in patients in treatment by dabigatran.
Topics: Aged; Antithrombins; Case-Control Studies; Dabigatran; Dental Implantation, Endosseous; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications | 2018 |
Direct new oral anticoagulants in the emergency department: Experience in everyday clinical practice at a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Switzerland | 2016 |
Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Disease-Free Survival; Drug Monitoring; Electronic Health Records; Female; Hemorrhage; Humans; Incidence; International Normalized Ratio; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Netherlands; Patient Safety; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2016 |
A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Area Under Curve; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Sensitivity and Specificity | 2016 |
Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Utilization Review; Electronic Health Records; Factor Xa Inhibitors; Female; Hemorrhage; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban | 2016 |
Screening coagulation tests are underutilised in patients on dabigatran presenting with thromboembolic or haemorrhagic events.
Topics: Aged; Antithrombins; Blood Coagulation Tests; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Thromboembolism | 2016 |
Prescriber compliance with renal function monitoring in patients taking dabigatran (Pradaxa).
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Female; Guideline Adherence; Hemorrhage; Humans; Kidney Function Tests; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2015 |
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Perioperative Period; Surgical Procedures, Operative; Thromboembolism; Warfarin | 2016 |
Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Retrospective Studies; Warfarin | 2017 |
[Dabigatran specific antidote: new safety level in oral anticoagulation].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Approval; Hemorrhage; Humans; Stroke | 2015 |
[Safer in everyday clinical care].
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Dabigatran; Emergency Medical Services; Hemorrhage; Humans; Patient Safety | 2015 |
[First NOAK with specific antidote].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Infusions, Intravenous; Stroke | 2015 |
The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Proportional Hazards Models; Prothrombin Time; Risk Factors; ROC Curve | 2016 |
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Ontario; Renal Insufficiency, Chronic; Risk; Rivaroxaban; Warfarin | 2016 |
[Anticoagulant activity is rapidly reversed].
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Hemorrhage; Humans | 2016 |
[First NOAk specific antidote as additional safety factor in therapy].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke | 2016 |
Reversal of lipophilic weak bases using pH gradient acidic centre liposomes: demonstration of effect in dabigatran-induced anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hemorrhage; Hydrogen-Ion Concentration; Liposomes; Rabbits; Rats; Rats, Sprague-Dawley; Thrombin; Time Factors | 2016 |
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Loss, Surgical; Cerebral Hemorrhage; Clinical Trials as Topic; Dabigatran; Drug Approval; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Which oral anticoagulant for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Patient Selection; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Management of bleeding complications in patients with cancer on DOACs.
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Topics: Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Warfarin | 2016 |
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Idarucizumab for Dabigatran Reversal Guideline.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Coagulants; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Thromboembolism | 2016 |
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Thromboembolism; United States; Warfarin | 2016 |
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dementia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism | 2016 |
Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Retrospective Studies; Stroke | 2016 |
Reversal of Dabigatran with Idarucizumab.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Thromboembolism | 2016 |
The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Transfusion; Case-Control Studies; Dabigatran; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Wounds and Injuries; Young Adult | 2016 |
Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Partial Thromboplastin Time; Renal Insufficiency; Retrospective Studies; Risk Factors; Stroke; Thromboembolism | 2017 |
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Italy; Logistic Models; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Vitamin K | 2016 |
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Stroke; Taiwan; Warfarin | 2017 |
Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Malaysia; Male; Medication Adherence; Middle Aged; Risk Factors; Stroke | 2016 |
Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Aortic Diseases; Atrial Fibrillation; Dabigatran; Emergencies; Hemorrhage; Humans; Male | 2016 |
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Topics: Administration, Oral; Advisory Committees; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban | 2016 |
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiac Surgical Procedures; Dabigatran; Emergencies; Female; Gastrointestinal Hemorrhage; Heart Transplantation; Hemorrhage; Hemostatics; Heparin; Humans; Incidence; International Normalized Ratio; Intracranial Hemorrhages; Laparotomy; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thrombocytopenia; Thromboembolism; Vitamin K; Warfarin | 2016 |
Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Nutrition Surveys; Outcome Assessment, Health Care; Pyridines; Renal Elimination; Rivaroxaban; Thiazoles; United States | 2016 |
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; United States; Warfarin; Young Adult | 2016 |
Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prodrugs; Stroke | 2016 |
Can the anticoagulant effects of dabigatran be reversed?
Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans | 2016 |
Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Combined Modality Therapy; Dabigatran; Female; Hemorrhage; Humans; Middle Aged; Renal Dialysis; Treatment Outcome | 2016 |
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Insurance Claim Review; Male; Medicare Part D; Rivaroxaban; Stroke; United States | 2017 |
Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Topics: Accidents, Traffic; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Retroperitoneal Space | 2016 |
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Norway; Prescription Drugs; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Survival Rate; Thromboembolism; Warfarin | 2017 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Internet; Patient Education as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2016 |
Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Drug Antagonism; Hemorrhage; Humans | 2017 |
[Safer treatment with serum concentration monitoring of the new anticoagulants?].
Topics: Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Reference Standards; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Hemostasis; Humans; Male; Severity of Illness Index; Treatment Outcome | 2017 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Thrombophilia; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2016 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Red Cell Distribution Width and Hemorrhagic Events Related to Dabigatran Use.
Topics: Benzimidazoles; Dabigatran; Erythrocyte Indices; Hemorrhage; Humans; Risk Factors | 2017 |
Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Aphasia; Atrial Fibrillation; Carotid Stenosis; Dabigatran; Emergencies; Emergency Service, Hospital; Endarterectomy, Carotid; Hemorrhage; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Spinal Puncture; Tomography, X-Ray Computed; Ultrasonography | 2017 |
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pulmonary Embolism; Research Design; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Bias; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Research Design; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medicaid; Medicare; Treatment Outcome; United States; Warfarin | 2017 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Rivaroxaban; Warfarin | 2017 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban | 2017 |
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Thrombosis; Vitamin K; Young Adult | 2017 |
Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.
Topics: Animals; Anticoagulants; Capillary Permeability; Dabigatran; Hemorrhage; Inflammation; Influenza A Virus, H1N1 Subtype; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Pulmonary Alveoli; Survival Analysis; Warfarin | 2016 |
Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Blood Coagulation; Dabigatran; Hemorrhage; Humans | 2017 |
[Monitoring of NOAC].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Emergency Service, Hospital; Hemorrhage; Humans; Intensive Care Units; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Hospital Mortality; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Recombinant Proteins; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Warfarin | 2017 |
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K | 2017 |
[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Electric Countershock; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Intensive Care Units; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin; Thromboembolism; Vitamin K | 2017 |
Anticoagulants: Updates on idarucizumab.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans | 2017 |
Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Erythrocyte Transfusion; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Retrospective Studies | 2017 |
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Data Collection; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Observational Studies as Topic; Patient Selection; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke; Warfarin | 2017 |
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Disease Management; Drug Interactions; Emergencies; Hemorrhage; Humans; Intracranial Hemorrhages; Middle Aged; Postoperative Hemorrhage; Thrombolytic Therapy | 2017 |
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER
Topics: Adult; Aged; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pulmonary Embolism; Stroke; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2017 |
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Erythrocyte Transfusion; Factor VIIa; Female; Hemorrhage; Hospital Mortality; Humans; Male; Medication Therapy Management; Ontario; Recombinant Proteins; Retrospective Studies; Stroke; Warfarin | 2017 |
Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies | 2017 |
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Confidence Intervals; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Odds Ratio; Ontario; Risk Factors; Stroke | 2017 |
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.
Topics: Adult; Anticoagulants; Antithrombins; Automation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Limit of Detection; Male; Middle Aged; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban; Thrombelastography | 2017 |
Dabigatran etexilate.
Topics: Anemia; Anticoagulants; Area Under Curve; Benzimidazoles; Dabigatran; Half-Life; Hemorrhage; Humans; Molecular Structure; Platelet Aggregation; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Suppuration; Surgical Wound Infection; Thromboembolism; Thrombosis; Treatment Outcome | 2008 |
Dabigatran etexilate for prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Enoxaparin; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Markov Chains; National Health Programs; Pyridines; United Kingdom; Venous Thromboembolism | 2009 |
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Topics: Animals; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Morpholines; Pyrazoles; Pyridines; Pyridones; Rabbits; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Drug Approval; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; France; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Vitamin K | 2009 |
[Stroke prevention in atrial fibrillation. Marcumar alternative in sight].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Phenprocoumon; Pyridines; Randomized Controlled Trials as Topic; Stroke; Vitamin K | 2009 |
At last, a RE-LYable alternative to warfarin for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dyspepsia; Hemorrhage; Humans; Multicenter Studies as Topic; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Warfarin | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Kidney Diseases; Postoperative Complications; Pyridines; United Kingdom; Venous Thromboembolism | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Patient Dropouts; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Hemorrhage; Humans; Incidence; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2009 |
Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Europe; Hemorrhage; Humans; Middle Aged; Multicenter Studies as Topic; North America; Pyridines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Venous Thromboembolism; Warfarin | 2010 |
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Meta-Analysis as Topic; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2010 |
Quality of anticoagulation control in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Multicenter Studies as Topic; Pyridines; Quality of Health Care; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Stroke; Warfarin | 2011 |
Newly identified events in the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Pyridines | 2010 |
Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk.
Topics: Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Pyridines; Stroke | 2010 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin | 2010 |
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Coagulation; Blood Platelets; Dabigatran; Enoxaparin; Fibrinolytic Agents; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Injections, Subcutaneous; Prosthesis Design; Pyridines; Swine; Thrombelastography; Thrombosis; Time Factors | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Female; Fracture Fixation; Hemiplegia; Hemorrhage; Humans; Ischemia; Postoperative Complications; Practice Guidelines as Topic; Prosthesis Failure; Risk; Stroke; Thrombolytic Therapy; Thrombosis | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Decision Trees; Hemorrhage; Humans; Markov Chains; Risk Factors; Stroke; Warfarin | 2011 |
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Patient Education as Topic; Warfarin | 2011 |
Periprocedural management of patients on dabigatran etexilate treatment.
Topics: Antithrombin Proteins; Benzimidazoles; Contraindications; Dabigatran; Hemorrhage; Humans; Neurosurgical Procedures; Perioperative Care; Postoperative Complications; Pyridines | 2011 |
Dabigatran in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Practice Guidelines as Topic | 2011 |
New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Pyridines; Risk Factors; Stroke | 2011 |
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Stroke; Warfarin | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Tolerance; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Stroke; Warfarin | 2011 |
Acutely injured patients on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Thrombelastography; Whole Blood Coagulation Time; Wounds and Injuries | 2011 |
Bleeding with dabigatran (Pradaxa).
Topics: Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; Humans; Pyridines; Renal Insufficiency; Stroke | 2011 |
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Splenic Diseases | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Feasibility Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Registries; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Countershock; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Risk Factors; Societies, Medical; Stroke; Ticlopidine; Vitamin K | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Initial experience with dabigatran etexilate at Auckland City Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; New Zealand; Patient Selection; Pyridines; Renal Insufficiency; Retrospective Studies | 2012 |
Dabigatran (Pradaxa).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Thrombosis | 2012 |
Bleeding risk with dabigatran in the frail elderly.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Frail Elderly; Hemorrhage; Humans; Product Surveillance, Postmarketing; Risk | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2012 |
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans; Hypotension; Respiratory Insufficiency; Severity of Illness Index | 2012 |
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Endopeptidases; Hemorrhage; Humans; Linear Models; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyridines; Reproducibility of Results; Risk Assessment; Risk Factors; Thrombin; Thrombin Time; Whole Blood Coagulation Time | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Hemorrhage; Humans; Patient Selection; Stroke; Warfarin | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Female; Heart Valve Prosthesis; Hemorrhage; Male; Mitral Valve; Models, Animal; Sus scrofa; Thrombosis; Warfarin | 2012 |
Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; Dabigatran; Female; Hemorrhage; Hemostatic Disorders; Humans; International Normalized Ratio; Male; Pyridines; Rectal Diseases | 2012 |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Guideline Adherence; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2012 |
Dabigatran: uncharted waters and potential harms.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pharmacovigilance; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Warfarin | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility Determination; Fees, Pharmaceutical; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Patient Preference; Patient Selection; Practice Patterns, Physicians'; Surveys and Questionnaires; United States; Warfarin | 2013 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dyspnea; Hemorrhage; Humans; Male; Pulmonary Alveoli; Pulmonary Fibrosis | 2013 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Stroke; Treatment Outcome; Warfarin | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Hemorrhagic complications associated with dabigatran use.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male | 2012 |
Diffuse alveolar hemorrhage associated with dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung Diseases; Male; Plasma; Radiography, Thoracic; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
A 77-year-old man with a prolonged activated partial thromboplastin time.
Topics: Aged; Anticoagulants; Autoantibodies; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male; Partial Thromboplastin Time | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Editorial critique.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Wounds and Injuries | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Europe; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Patient Selection; Preventive Health Services; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
Dabigatran: a cause of hematologic emergency.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
Topics: Adrenal Gland Diseases; Adrenal Insufficiency; Aged; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pulmonary Embolism; Tissue Plasminogen Activator | 2013 |
When dabigatran and trauma collide.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle Aged; Wounds and Injuries | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |